

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6143058

|                                                                                                                                                                                                 |                              |                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-----------------------|
| <b>SUBMISSION TYPE:</b>                                                                                                                                                                         | NEW ASSIGNMENT               |                       |
| <b>NATURE OF CONVEYANCE:</b>                                                                                                                                                                    | SECURITY INTEREST            |                       |
| <b>CONVEYING PARTY DATA</b>                                                                                                                                                                     |                              |                       |
|                                                                                                                                                                                                 | <b>Name</b>                  | <b>Execution Date</b> |
|                                                                                                                                                                                                 | ADC THERAPEUTICS SA          | 05/19/2020            |
| <b>RECEIVING PARTY DATA</b>                                                                                                                                                                     |                              |                       |
| <b>Name:</b>                                                                                                                                                                                    | DEERFIELD PARTNERS, L.P.     |                       |
| <b>Street Address:</b>                                                                                                                                                                          | 780 THIRD AVENUE, 37TH FLOOR |                       |
| <b>City:</b>                                                                                                                                                                                    | NEW YORK                     |                       |
| <b>State/Country:</b>                                                                                                                                                                           | NEW YORK                     |                       |
| <b>Postal Code:</b>                                                                                                                                                                             | 10017                        |                       |
| <b>PROPERTY NUMBERS Total: 1</b>                                                                                                                                                                |                              |                       |
|                                                                                                                                                                                                 | <b>Property Type</b>         | <b>Number</b>         |
|                                                                                                                                                                                                 | Patent Number:               | 9931415               |
| <b>CORRESPONDENCE DATA</b>                                                                                                                                                                      |                              |                       |
| <b>Fax Number:</b>                                                                                                                                                                              | (608)662-1276                |                       |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                              |                       |
| <b>Phone:</b>                                                                                                                                                                                   | 6086621277                   |                       |
| <b>Email:</b>                                                                                                                                                                                   | maschur@casimirjones.com     |                       |
| <b>Correspondent Name:</b>                                                                                                                                                                      | MELISSA E. KOLOM             |                       |
| <b>Address Line 1:</b>                                                                                                                                                                          | 2275 DEMING WAY              |                       |
| <b>Address Line 2:</b>                                                                                                                                                                          | SUITE #310                   |                       |
| <b>Address Line 4:</b>                                                                                                                                                                          | MIDDLETON, WISCONSIN 53562   |                       |
| <b>ATTORNEY DOCKET NUMBER:</b>                                                                                                                                                                  | MEWB-35694.256               |                       |
| <b>NAME OF SUBMITTER:</b>                                                                                                                                                                       | MELISSA E. KOLOM             |                       |
| <b>SIGNATURE:</b>                                                                                                                                                                               | /Melissa E. Kolom/           |                       |
| <b>DATE SIGNED:</b>                                                                                                                                                                             | 06/08/2020                   |                       |
| <b>Total Attachments: 114</b>                                                                                                                                                                   |                              |                       |
| source=ADC-Deerfield-Pledge#page1.tif                                                                                                                                                           |                              |                       |
| source=ADC-Deerfield-Pledge#page2.tif                                                                                                                                                           |                              |                       |
| source=ADC-Deerfield-Pledge#page3.tif                                                                                                                                                           |                              |                       |
| source=ADC-Deerfield-Pledge#page4.tif                                                                                                                                                           |                              |                       |
| source=ADC-Deerfield-Pledge#page5.tif                                                                                                                                                           |                              |                       |

source=ADC-Deerfield-Pledge#page6.tif  
source=ADC-Deerfield-Pledge#page7.tif  
source=ADC-Deerfield-Pledge#page8.tif  
source=ADC-Deerfield-Pledge#page9.tif  
source=ADC-Deerfield-Pledge#page10.tif  
source=ADC-Deerfield-Pledge#page11.tif  
source=ADC-Deerfield-Pledge#page12.tif  
source=ADC-Deerfield-Pledge#page13.tif  
source=ADC-Deerfield-Pledge#page14.tif  
source=ADC-Deerfield-Pledge#page15.tif  
source=ADC-Deerfield-Pledge#page16.tif  
source=ADC-Deerfield-Pledge#page17.tif  
source=ADC-Deerfield-Pledge#page18.tif  
source=ADC-Deerfield-Pledge#page19.tif  
source=ADC-Deerfield-Pledge#page20.tif  
source=ADC-Deerfield-Pledge#page21.tif  
source=ADC-Deerfield-Pledge#page22.tif  
source=ADC-Deerfield-Pledge#page23.tif  
source=ADC-Deerfield-Pledge#page24.tif  
source=ADC-Deerfield-Pledge#page25.tif  
source=ADC-Deerfield-Pledge#page26.tif  
source=ADC-Deerfield-Pledge#page27.tif  
source=ADC-Deerfield-Pledge#page28.tif  
source=ADC-Deerfield-Pledge#page29.tif  
source=ADC-Deerfield-Pledge#page30.tif  
source=ADC-Deerfield-Pledge#page31.tif  
source=ADC-Deerfield-Pledge#page32.tif  
source=ADC-Deerfield-Pledge#page33.tif  
source=ADC-Deerfield-Pledge#page34.tif  
source=ADC-Deerfield-Pledge#page35.tif  
source=ADC-Deerfield-Pledge#page36.tif  
source=ADC-Deerfield-Pledge#page37.tif  
source=ADC-Deerfield-Pledge#page38.tif  
source=ADC-Deerfield-Pledge#page39.tif  
source=ADC-Deerfield-Pledge#page40.tif  
source=ADC-Deerfield-Pledge#page41.tif  
source=ADC-Deerfield-Pledge#page42.tif  
source=ADC-Deerfield-Pledge#page43.tif  
source=ADC-Deerfield-Pledge#page44.tif  
source=ADC-Deerfield-Pledge#page45.tif  
source=ADC-Deerfield-Pledge#page46.tif  
source=ADC-Deerfield-Pledge#page47.tif  
source=ADC-Deerfield-Pledge#page48.tif  
source=ADC-Deerfield-Pledge#page49.tif  
source=ADC-Deerfield-Pledge#page50.tif  
source=ADC-Deerfield-Pledge#page51.tif  
source=ADC-Deerfield-Pledge#page52.tif  
source=ADC-Deerfield-Pledge#page53.tif

source=ADC-Deerfield-Pledge#page54.tif  
source=ADC-Deerfield-Pledge#page55.tif  
source=ADC-Deerfield-Pledge#page56.tif  
source=ADC-Deerfield-Pledge#page57.tif  
source=ADC-Deerfield-Pledge#page58.tif  
source=ADC-Deerfield-Pledge#page59.tif  
source=ADC-Deerfield-Pledge#page60.tif  
source=ADC-Deerfield-Pledge#page61.tif  
source=ADC-Deerfield-Pledge#page62.tif  
source=ADC-Deerfield-Pledge#page63.tif  
source=ADC-Deerfield-Pledge#page64.tif  
source=ADC-Deerfield-Pledge#page65.tif  
source=ADC-Deerfield-Pledge#page66.tif  
source=ADC-Deerfield-Pledge#page67.tif  
source=ADC-Deerfield-Pledge#page68.tif  
source=ADC-Deerfield-Pledge#page69.tif  
source=ADC-Deerfield-Pledge#page70.tif  
source=ADC-Deerfield-Pledge#page71.tif  
source=ADC-Deerfield-Pledge#page72.tif  
source=ADC-Deerfield-Pledge#page73.tif  
source=ADC-Deerfield-Pledge#page74.tif  
source=ADC-Deerfield-Pledge#page75.tif  
source=ADC-Deerfield-Pledge#page76.tif  
source=ADC-Deerfield-Pledge#page77.tif  
source=ADC-Deerfield-Pledge#page78.tif  
source=ADC-Deerfield-Pledge#page79.tif  
source=ADC-Deerfield-Pledge#page80.tif  
source=ADC-Deerfield-Pledge#page81.tif  
source=ADC-Deerfield-Pledge#page82.tif  
source=ADC-Deerfield-Pledge#page83.tif  
source=ADC-Deerfield-Pledge#page84.tif  
source=ADC-Deerfield-Pledge#page85.tif  
source=ADC-Deerfield-Pledge#page86.tif  
source=ADC-Deerfield-Pledge#page87.tif  
source=ADC-Deerfield-Pledge#page88.tif  
source=ADC-Deerfield-Pledge#page89.tif  
source=ADC-Deerfield-Pledge#page90.tif  
source=ADC-Deerfield-Pledge#page91.tif  
source=ADC-Deerfield-Pledge#page92.tif  
source=ADC-Deerfield-Pledge#page93.tif  
source=ADC-Deerfield-Pledge#page94.tif  
source=ADC-Deerfield-Pledge#page95.tif  
source=ADC-Deerfield-Pledge#page96.tif  
source=ADC-Deerfield-Pledge#page97.tif  
source=ADC-Deerfield-Pledge#page98.tif  
source=ADC-Deerfield-Pledge#page99.tif  
source=ADC-Deerfield-Pledge#page100.tif  
source=ADC-Deerfield-Pledge#page101.tif

source=ADC-Deerfield-Pledge#page102.tif  
source=ADC-Deerfield-Pledge#page103.tif  
source=ADC-Deerfield-Pledge#page104.tif  
source=ADC-Deerfield-Pledge#page105.tif  
source=ADC-Deerfield-Pledge#page106.tif  
source=ADC-Deerfield-Pledge#page107.tif  
source=ADC-Deerfield-Pledge#page108.tif  
source=ADC-Deerfield-Pledge#page109.tif  
source=ADC-Deerfield-Pledge#page110.tif  
source=ADC-Deerfield-Pledge#page111.tif  
source=ADC-Deerfield-Pledge#page112.tif  
source=ADC-Deerfield-Pledge#page113.tif  
source=ADC-Deerfield-Pledge#page114.tif

---

# IP Pledge Agreement

dated 19 May 2020

by and between

---

ADC Therapeutics SA (the Pledgor)  
Biopôle  
route de la Corniche 3 B  
1066 Epalinges  
Switzerland

and

---

Deerfield Partners, L.P. (the Security Agent)  
780 Third Avenue, 37th Floor  
New York, NY 10017  
USA

as security agent and pledgee, acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of all other Secured Parties

and

---

the Secured Parties (the Pledgees)

represented for all purposes hereof by the Security Agent as direct representative (*direkter Stellvertreter*)

regarding

---

the pledge of all the Intellectual Property and Related Assets of the Pledgor

---

**Table of Contents**

|            |                                                               |           |
|------------|---------------------------------------------------------------|-----------|
| <b>1.</b>  | <b>Definitions and construction .....</b>                     | <b>4</b>  |
| 1.1.       | Definitions.....                                              | 4         |
| 1.2.       | Construction .....                                            | 8         |
| <b>2.</b>  | <b>Pledge and Pledgor's obligations .....</b>                 | <b>9</b>  |
| 2.1.       | Undertaking to pledge .....                                   | 9         |
| 2.2.       | Effecting of the Pledge.....                                  | 9         |
| 2.3.       | Registration.....                                             | 9         |
| <b>3.</b>  | <b>Intellectual Property.....</b>                             | <b>10</b> |
| 3.1.       | Right to use Intellectual Property.....                       | 10        |
| 3.2.       | Information duties .....                                      | 11        |
| <b>4.</b>  | <b>Representations and warranties .....</b>                   | <b>12</b> |
| <b>5.</b>  | <b>Further undertakings of the Pledgor .....</b>              | <b>13</b> |
| <b>6.</b>  | <b>Enforcement.....</b>                                       | <b>15</b> |
| <b>7.</b>  | <b>Conditional assignment .....</b>                           | <b>16</b> |
| <b>8.</b>  | <b>Allocation and application of proceeds.....</b>            | <b>17</b> |
| <b>9.</b>  | <b>Additional Pledges; authorisation.....</b>                 | <b>17</b> |
| <b>10.</b> | <b>Continuing Security; effectiveness of collateral .....</b> | <b>18</b> |
| <b>11.</b> | <b>Release of Pledged Assets .....</b>                        | <b>19</b> |
| <b>12.</b> | <b>Reinstatement and avoidance of payments .....</b>          | <b>19</b> |
| <b>13.</b> | <b>Miscellaneous .....</b>                                    | <b>20</b> |
| 13.1.      | Costs and expenses.....                                       | 20        |
| 13.2.      | Waivers and amendment .....                                   | 20        |
| 13.3.      | Assignment or transfer .....                                  | 20        |
| 13.4.      | Notices .....                                                 | 21        |
| 13.5.      | Severability .....                                            | 21        |
| 13.6.      | Counterparts.....                                             | 21        |

|                                                                                                                    |     |
|--------------------------------------------------------------------------------------------------------------------|-----|
| 14. Law and jurisdiction .....                                                                                     | 21  |
| Schedule 1: Existing Intellectual Property .....                                                                   | 24  |
| Schedule 2a: Form of Notification Letter to the World Institute of Intellectual Property<br>Organisation .....     | 110 |
| Schedule 2b: Form of Notification Letter to Swiss Federal Institute of Intellectual<br>Property (trademarks) ..... | 111 |
| Schedule 2c: Form of Notification Letter to Swiss Federal Institute of Intellectual<br>Property (patents) .....    | 112 |

---

**WHEREAS**

- A. On 24 April 2020, a facility agreement has been entered into between, amongst others, ADC Therapeutics SA as Borrower, the Lenders named therein and Deerfield Partners, L.P. as Agent (all as defined therein) (the **Facility Agreement**).
- B. It is a condition under the Facility Agreement that, as Security (as defined below) for the due and punctual fulfilment of the Secured Obligations (as defined below), the Pledgor grants a pledge to the Pledgees over the Pledged Assets (as defined below).
- C. In accordance with section 9.13 (*Agent*) of the Facility Agreement and more specifically in accordance with paragraph (b) of section 9.13 (*Agent*) of the Facility Agreement, each Secured Party has appointed the Security Agent to enter into this Agreement for itself and for and on behalf of each other Secured Party as direct representative (*direkter Stellvertreter*) and to hold the Security hereby constituted as direct representative (*direkter Stellvertreter*) for itself and for all other Secured Parties.
- D. The Pledgor is willing to pledge the Pledged Assets to the Pledgees as provided herein.

**NOW THEREFORE**, the parties hereto (the **Parties**) agree as follows:

---

**1. Definitions and construction**
**1.1. Definitions**

Unless defined otherwise herein, capitalised terms and expressions used herein shall have the meaning ascribed to them in the Facility Agreement.

When used in this Agreement only, the following capitalised terms shall have the meaning assigned to them below:

**Agreement** means this IP pledge agreement and its schedules.



**CC** means the Swiss Civil Code (*Schweizerisches Zivilgesetzbuch*) dated 10 December 1907.

**Clause** means a clause of this Agreement.

**CO** means the Swiss Code of Obligations (*Schweizerisches Obligationenrecht*) dated 30 March 1911.

**Collateral Rights** means all rights, powers and remedies of the Security Agent or the Pledgees provided by this Agreement or by law.

**DEBA** means the Swiss Debt Collection and Bankruptcy Act (*Bundesgesetz über Schuldbetreibung und Konkurs*) dated 11 April 1889.

**Declared Default** means the occurrence of an Event of Default which has been accelerated in accordance with the terms of the Finance Documents.

**Enforcement** means the enforcement, foreclosure or any other kind of realisation of the Pledged Assets.

**Facility Agreement** has the meaning given to it in section A. of the preamble to this Agreement.

**Finance Documents** means the Facility Documents as defined in the Facility Agreement.

**Group** means the Pledgor and each of its Subsidiaries for the time being.

**Intellectual Property** means:

- (a) all rights, titles and interests it has under any copyright or other intellectual property law, including without limitation any copyrights in software, databases, other works or any computer programming code (in readable form) of any such software, databases or other work (the **Copyrights**), patents (the **Patents**), trademarks (the **Trademarks**) and domain names (the **Domain Names**), worldwide, owned as of the date hereof or acquired in the future by the Pledgor, in each case whether registered or not (including those as set-out in Schedule 1);
- (b) all pending or future applications for, and the rights to make applications for, any of those rights set forth in (a) above (where such

applications can be made), including, without limitation, the pending trademark applications as outlined in Schedule 1 of this Agreement;

- (c) all rights which have the same or similar effect or nature as or to those in (a) or (b) above or which would in any way prevent or hinder the use or exploitation of the matter to which they relate, in each case worldwide; and
- (d) in each case of (a), (b) and (c) except for any assets situated in England and Wales.

**Pledge** means a pledge pursuant to art. 899 et seq. CC of the Pledged Assets in accordance with the terms of this Agreement.

**Pledged Assets** means the Intellectual Property and Related Assets or any other security or asset that is to be or will be pledged to the Pledgees under this Agreement.

**Pledgees** means all existing Secured Parties as well as any future Secured Party which becomes a Pledgee pursuant to Clause 9(a) (*Additional Pledgees*; ), but excluding any person which pursuant to Clause 9(a) (*Additional Pledgees*; ) has ceased to be a Pledgee.

**Pledgor** has the meaning given to it on the cover page of this Agreement.

**Related Assets** means, all and any rights, claims or benefits in respect of or derived from the Intellectual Property, including without limitation, claims for damages or claims against an insurance provider in case of loss or damage to the Intellectual Property, to the extent such rights are assignable.

**Secured Obligations** means, all present and future obligations and liabilities (whether actual or contingent, whether owed jointly, severally or in any other capacity whatsoever) of the Pledgor (or any other member of the Group) to and towards the Secured Parties under and/or in connection with any Finance Document (including any convertible note or any similar instrument, in particular the Convertible Notes), together with any of the following matters relating to or arising in respect of those liabilities and obligations:

- (a) any refinancing, novation, deferral or extension;
- (b) any claim for damages or restitution; and

- (c) any claim as a result of any recovery by the Pledgor of a payment or discharge on the grounds of preference,

and any amounts which would be included in any of the above but for any discharge, non-provability or unenforceability of those amounts in any insolvency or other proceedings. The Secured Obligations shall include any obligation based on unjust enrichment (*ungerechtfertigte Bereicherung*) or tort (*Delikt*).

**Secured Parties** has the meaning given to it in the Facility Agreement.

**Security** means a mortgage, charge, pledge, lien or other security interest having a similar effect.

**Security Agent** has the meaning given to it on the cover page of this Agreement.

**Selected Jurisdictions** means: Australia, Canada, New Zealand, South Africa, United States of America, European Patent Office, Belgium, Czech Republic, Germany, Denmark, Estonia, Finland, France, Hungary, Ireland, Iceland, Luxembourg, Malta, Netherlands, Norway, Portugal, Sweden, Slovenia.

**Subsidiary** means in relation to any company, corporation or partnership, any company, corporation or partnership:

- (a) of which that person has direct or indirect control; and
- (b) of which a person has direct or indirect control or owns directly or indirectly more than 50 per cent. of the voting capital or similar right of ownership,

and for this purpose "control" means the direct or indirect ownership of a majority of the voting share capital or similar ownership rights of that entity, or the right or ability to determine the composition of a majority of the board of directors (or equivalent body) of such company, corporation or partnership or otherwise to direct the management of such entity whether by virtue of ownership of share capital, contract or otherwise.

**Swiss Civil Procedure Code** means the Swiss Federal Civil Procedure Code (*Zivilprozessordnung, ZPO*) dated 19 December 2008.

**1.2. Construction**

- (a) In this Agreement, section 1.2 of the Facility Agreement shall apply *mutatis mutandis* to this Agreement.
- (b) In addition, in this Agreement:
  - (i) references to any agreement or other document are references to such agreement or document as amended, restated, novated, supplemented, extended or replaced, from time to time, in accordance with its terms and includes any change in the purpose of, any extension of or any increase in any facility, any increase in any margin, or the addition of any new facility under that agreement or document;
  - (ii) references to Clauses and Schedules are references to clauses of and schedules to this Agreement;
  - (iii) words importing the plural shall include the singular and vice versa; and
  - (iv) "including" means "including without limitation", not limiting the term(s) to which the word relates to the example(s) thereafter mentioned; and
  - (v) unless the context requires otherwise, references herein to the Security Agent shall be read as references to the Security Agent acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees.
- (c) If any terms of this Agreement are contradictory to the Facility Agreement, then the latter shall prevail and such contradiction shall not be considered a breach under this Agreement, it being understood that the validity, legality and enforceability of this Agreement shall not in any way be affected or impaired.

---

## **2. Pledge and Pledgor's obligations**

### **2.1. Undertaking to pledge**

The Pledgor hereby agrees to pledge to the Pledgees, directly represented by the Security Agent, acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees, the Pledged Assets free and clear of any Security in favour of third parties and as continuing first ranking Security for the Secured Obligations.

### **2.2. Effecting of the Pledge**

- (a) For the purposes of effecting the Pledge as described in Clause 2.1 (*Undertaking to pledge*), the Pledgor hereby pledges with immediate effect as per the date hereof all Pledged Assets to the Pledgees, directly represented by the Security Agent, acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees, as a continuing first ranking Security, free and clear of any Security in favour of third parties in order to secure the Secured Obligations.
- (b) The Pledge of the Pledged Assets shall be effective as of the date hereof and shall be valid regardless of whether or not such Pledge can be registered and regardless of whether or not the Pledge is or will be registered with the competent registration organisation.

### **2.3. Registration**

- (a) With respect to the Intellectual Property other than Domain Names, the Pledgor herewith (i) undertakes to notify the Pledge to the Swiss Federal Institute of Intellectual Property, all other competent trademark offices and authorities and/or third parties, as applicable, and to submit the Pledge for registration to the Swiss Federal Institute of Intellectual Property, trademark registers or any other registers, as applicable, of each Selected Jurisdiction within thirty (30) Business Days and make its best efforts to effect the registrations and (ii) authorizes the Security Agent to make any notifications and registrations in connection with the Pledge. For the purpose of 2.3 (a)(ii), the Pledgor shall within thirty (30)

Business Days from the date of this Agreement deliver to the Security Agent prepared and signed notification letters, inter alia, in the form as attached to in Schedules 2a, 2b and 2c as the case may be, or otherwise applicable and required as the case may be; the Pledgor shall, at the reasonable request of the Security Agent, further take all measures and acts and execute and deliver all written instruments and declarations required to perfect, protect and maintain the registration of such Pledge.

- (b) With respect to such Intellectual Property which the Pledgor does not hold exclusive ownership of, upon the Security Agent's request, the Pledgor will provide a consent letter in writing signed by each co-owner of such Intellectual Property acknowledging to and agreeing with the Pledge and the registration of the Pledge in the respective Intellectual Property register within fifteen (15) Business Days following the request of the Security Agent.
- (c) With respect to the Domain Names, the Pledgor herewith authorises the Security Agent to notify the Pledge to all competent offices, other authorities and/or third parties, as applicable, and to register the Pledge in Switzerland and any Selected Jurisdiction. Therefore, the Pledgor shall at its sole costs and expenses, promptly upon request of the Security Agent, prepare, sign and deliver to the Security Agent signed notification letters and/or any document otherwise applicable and provided by the Security Agent.
- (d) Paragraphs (a), (b) and (c) of this Clause 2.3 (*Registration*) shall apply *mutatis mutandis* in case the Pledgor acquires any additional Intellectual Property in Switzerland or any Selected Jurisdiction in the future, whether by registration, purchase or otherwise.

---

### **3. Intellectual Property**

#### **3.1. Right to use Intellectual Property**

- (a) For so long as no Event of Default has occurred, the Pledgor shall retain, and the Security Agent, acting on its own behalf and on behalf of each Pledgee, hereby acknowledges that the Pledgor has and authorises and grants the Pledgor the sole and exclusive right and authority to use the

Pledged Assets at its sole discretion and for its own account in the course of business, subject to and in accordance with the Finance Documents. For the avoidance of doubt, other than as expressly set forth in the Finance Documents (including this Agreement), the Pledgor shall in no way or manner be limited in its use and exploitation of the Pledged Assets.

- (b) Upon and following the occurrence of an Event of Default,
  - (i) the Pledgor shall in no event take actions that could adversely affect (x) the validity and/or enforceability of the security interest created under this Agreement and/or (y) the value of the Pledged Assets; and
  - (ii) upon being notified by the Security Agent, the Pledgor shall no longer be entitled to use the Pledged Assets (including to grant, extend or otherwise amend licenses) without the prior written consent of the Security Agent.
- (c) Irrespective of and in addition to the foregoing, the Security Agent shall be entitled to revoke the power of attorney granted under paragraph (a) of this Clause at any time where an event or a circumstance makes a revocation necessary in the reasonable discretion of the Security Agent in order to perfect, maintain or protect the Security created under this Agreement and/or the Collateral Rights.

### **3.2. Information duties**

- (a) On the date of this Agreement, the Pledgor shall provide the Security Agent with a list of the Intellectual Property as of the date hereof, in the form set out in Schedule 1.
- (b) The Pledgor shall provide the Security Agent, (i) on the date of this Agreement and then (ii) within one hundred and fifty (150) days after the end of each fiscal year of the Pledgor, or (iii) in any event as from an Event of Default which is continuing upon the Security Agent's request (acting reasonably), with correct, complete and up-to-date lists of Intellectual Property in the form set out in Schedule 1. Such lists of Intellectual Property are of declaratory nature and the Pledged Assets

are pledged irrespective of whether or not the Intellectual Property or the Pledged Assets have been or will be listed.

---

**4. Representations and warranties**

- (a) The Pledgor represents and warrants to the Security Agent acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees as at the date hereof and during the subsistence of this Agreement as follows:
  - (i) it is the sole legal owner of the Intellectual Property and the Pledged Assets;
  - (ii) the Pledged Assets have not been assigned or pledged or otherwise encumbered and are free and clear of any Security (except as created under this Agreement and except Security permitted to exist under the Finance Documents) and/or any restriction on the ability to encumber, transfer or realise all or any part of the Pledged Assets;
  - (iii) all Pledged Assets have been validly created and, to the extent registration is possible, the registered Intellectual Property set out in Schedule 1 are properly registered in the name of the Pledgor with the competent registration organisation;
  - (iv) all details regarding the Intellectual Property set out in Schedule 1 are correct, accurate, complete and up-to-date;
  - (v) it is validly existing, has the power to enter into and perform its obligations under this Agreement and all consents, approvals and authorisations have been obtained to make the Pledge valid, binding and enforceable in accordance with the terms of this Agreement;
  - (vi) this Agreement constitutes legal and valid obligations, binding upon the Pledgor and is an effective Security over the Pledged Assets; and
  - (vii) no board's or shareholders' resolution (or similar resolution) of the Pledgor, has been passed or approved nor has any application been made with respect to the Pledgor in relation to bankruptcy,



voluntary or judicial liquidation, composition with creditors, suspension of payments, controlled management, general settlement with creditors, reorganisation or similar legal proceedings which would be likely have an adverse effect (in terms of value, enforceability or otherwise) on the Pledge and/or the Pledged Assets or any other right of the Security Agent or any other Pledgee under this Agreement.

- (b) The representations and warranties in this Clause 4 (*Representations and warranties*) shall be in addition to and not in lieu of the representations and warranties of the Pledgor in the other Finance Documents and are made by the Pledgor by reference to the facts and circumstances existing as of the date of this Agreement and are deemed to be repeated on, and by reference to the facts and circumstances then existing on, and as of any Disbursement Date and as of the date of each Perfection Certificate, from the date of this Agreement until the release of the Pledged Assets.

---

## 5. Further undertakings of the Pledgor

Without prejudice and in addition to the undertakings of the Pledgor or any other Loan Party under the Facility Agreement and any other Finance Document, the Pledgor hereby undertakes to the Security Agent and the Pledgees as follows:

- (a) to promptly execute and deliver at its own cost and expense all further instruments and documents, and take all further action, that the Security Agent may reasonably request or that are required as a matter of law, in order to (i) perfect, register (subject to Clause 2.3 (*Registration*)), protect, secure, maintain and enforce the Security created or contemplated by this Agreement, (ii) facilitate the exercise of the Security Agent's and Pledgees' Collateral Rights and (iii) enable the Security Agent and the other Pledgees to transfer and assign this Agreement or any rights or obligations hereunder (including the Security over the Pledged Assets) in accordance with Clause 13.3 (*Assignment or transfer*);
- (b) at its own expense, to enter into and procure the perfection of additional pledge or security agreements, if and to the extent that a Pledge of certain Related Assets requires as a matter of law, the

execution and perfection of a specific pledge or security agreement and/or any other action for such Related Assets;

- (c) except with the Security Agent's prior written consent or unless expressly permitted otherwise under the Finance Documents, not to:
  - (i) do, or permit to be done, anything which would adversely affect the priority, ranking, legality, validity and enforceability or value of the Security created or expressed to be created pursuant to this Agreement and/or the Collateral Rights,
  - (ii) enter into any legal instrument relating to, or granting any Security over, or dispose of, or assign its Pledged Assets, or
  - (iii) take any other action with respect to the Pledged Assets that would jeopardise any rights of the Security Agent and/or the Pledgees under the Pledge, or would jeopardise the Enforcement of the Pledged Assets;
- (d) to immediately notify the Security Agent of, and provide the Security Agent with all information relating to, any occurrence which has or would have an adverse effect on the Pledge and/or on the Pledged Assets (including any material infringement, misappropriation or dilution or threatened or suspected material infringement misappropriation or dilution of or any challenge to the validity of any such Intellectual Property owned by it) in order to allow the Security Agent to effectively ensure that the value and validity of the Pledge and/or the Collateral Rights is perfected and maintained;
- (e) immediately upon becoming aware of any litigation in respect of any Intellectual Property, to notify the Security Agent thereof and to provide the Security Agent with all information relating thereto. Upon the occurrence of an Event of Default, the Security Agent shall have the right, but not the obligation to give the Pledgor binding instructions or to join the Pledgor in any such litigation or, if permitted by law, to litigate on behalf of the Pledgor in case of a litigation in respect of the Intellectual Property; and
- (f) to take all legal and other actions which are necessary to safeguard the Security Agent's and the other Pledgees' rights under or in respect of the Pledged Assets.

---

## 6. Enforcement

- (a) Upon the occurrence of a Declared Default, the Security Agent (acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees) shall be entitled (but not obliged), at its full discretion and without prior notice to the Pledgor or any other party, to:
  - (i) effect Enforcement by either (1) private realisation (*Privatverkauf*, including, to the extent legally permitted self-sale (*Selbsteintritt*) of the Pledged Assets or (2) enforcement proceedings pursuant to the DEBA under the exclusion of article 41 para 1<sup>bis</sup> DEBA (waiver of the *beneficium excussionis realis*) and the Parties agree in advance that a "*Freihandverkauf*" shall be admissible;
  - (ii) act as Security Agent contracting in its own name and in the name of the Pledgees and on its own and their accounts or for the account of third persons in private or official Enforcement; and
  - (iii) apply all monies arising from the Pledged Assets as though they were the proceeds of an Enforcement under this Agreement.
- (b) Failure by the Security Agent or any Pledgee to sell Pledged Assets or to exercise any right or remedy shall not result in any liability of the Security Agent or any Pledgee and shall not prejudice any of the rights the Security Agent and the Pledgees may have under this Agreement or any other of the Finance Documents, nor be a waiver of any obligation of the Pledgor hereunder and/or thereunder.
- (c) Notwithstanding previous enforcement actions with respect to the Pledged Assets without formality or notice, the Security Agent retains the right at all times to take any measure it deems necessary or appropriate in accordance with the DEBA or any analogous provisions under applicable foreign law.
- (d) The Security Agent shall not be bound to enforce any other Security before enforcing the Security created by this Agreement.
- (e) The Security Agent shall be free to enforce all or only part of the Pledged Assets and to determine the order of enforcement into the Pledged Assets.

- (f) The Security Agent shall be entitled to enforce the Pledge in respect of all or only part of the Security. Such partial enforcement shall not affect the Pledge on the remaining Security.
- (g) The Pledgor agrees that the Security Agent can instruct a third party to conduct the Enforcement of the Pledge for its account.
- (h) In connection with an Enforcement under this Agreement, the Pledgor:
  - (i) waives any right of requesting that the Pledged Assets be realised before foreclosure in any of its other assets or before exercise of any other Security which may have been granted to the Security Agent and/or the other Secured Parties for the Secured Obligations;
  - (ii) shall at the request of the Security Agent fully co-operate with the Security Agent and use its best efforts in assisting the Security Agent with regard to the Enforcement; and
  - (iii) shall upon request of the Security Agent, provide the Security Agent free of charge with all information, records and documents that are required or requested for the purpose of enforcing this Agreement, in copy or, if necessary or requested by the Security Agent, in original.

---

## 7. Conditional assignment

To the extent that the Pledge on the Intellectual Property and the Related Assets cannot be perfected and/or enforced under Clauses 2 (*Pledge and Pledgor's obligations*), 5 (*Further undertakings of the Pledgor*) or 6 (*Enforcement*) under applicable law, this Agreement, upon the occurrence of an Event of Default, constitutes a conditional assignment pursuant to art. 164 et seq. CO by way of security (*Sicherungscession*) and/or the transfer of title by way of security (*Sicherungsübereignung*), as the case may be, of said Intellectual Property and Related Assets from the Pledgor to the Security Agent, acting for itself and as a fiduciary for the account of each Secured Party, allowing the Security Agent, to perfect (i) private realisation or (ii) institute enforcement proceedings each as stated in Clause 6 (*Enforcement*).

---

**8. Allocation and application of proceeds**

Any proceeds received hereunder by a Secured Party, in particular any proceeds received under Clause 6 (*Enforcement*), shall be applied in accordance with the Finance Documents.

---

**9. Additional Pledges; authorisation**

- (a) The Pledgor acknowledges and agrees that the Security Agent is entering into this Agreement acting as representative (*direkter Stellvertreter*) pursuant to section 9.13 (*Agent*) of the Facility Agreement and more specifically in accordance with paragraph (b) of section 9.13 (*Agent*) of the Facility Agreement for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledges and that for such purpose upon an additional person becoming a Secured Party under the Facility Agreement, such new Secured Party shall automatically become a Pledgee hereunder and any Secured Party which has ceased to be a Secured Party shall automatically cease to be a Pledgee hereunder.
- (b) The Pledgor authorises the Security Agent to be its authorised representative, and in its name, on its behalf and as its act and deed to execute, deliver and perfect all documents and do all things that the Security Agent may consider to be requisite for carrying out any obligation imposed on the Pledgor under this Agreement or exercising any of the rights conferred on the Security Agent or the Pledges by this Agreement or by law, in particular in connection with a private realisation (*Private Verwertung*, including, without limitation, self-sale (*Selbsteintritt*)), provided that such authorisation granted hereunder shall not be exercisable unless:
  - (i) a Declared Default has occurred; or
  - (ii) the Pledgor has materially failed to comply with a written request to fulfil a further assurance or perfection or other obligation within any grace period applicable thereto.

---

**10. Continuing Security; effectiveness of collateral**

- (a) The Pledge constitutes a continuing Security which shall be cumulative, in addition to and independent of every other Security which the Security Agent or any other Secured Party may at any time hold for the Secured Obligations or any rights, powers and remedies provided by law.
- (b) The Security expressed to be created under this Agreement shall not be affected in any way by any variation, amendment, restatement, novation, transfer (including by way of novation), extension, compromise or release of any or all of the Secured Obligations or the Finance Documents or of any other Security from time to time.
- (c) The Pledgor agrees that no rights and claims shall pass to or otherwise arise for the benefit of the Pledgor by subrogation (*gesetzlicher Übergang von Forderungen und Rechten*) or otherwise, including any recourse claims, indemnification claims, claims arising from unjust enrichment (*ungerechtfertigte Bereicherung*) and any right to demand the assignment and/or transfer of any Secured Obligations and/or Security, against any obligor, grantor of Security or Secured Party (as the case may be) which the Pledgor may (but for this paragraph) be entitled to as a result of:
  - (i) a payment or repayment by the Pledgor of any debt of any other obligor under any of the Finance Documents; or
  - (ii) in case of Enforcement of the Pledge (or any part thereof).

The Pledgor furthermore undertakes (i) not to exercise (*pactum de non petendo*), and not to purport to exercise, any such rights and claims which may pass to it or otherwise arise for its benefit notwithstanding this paragraph or would pass to it or otherwise arise for its benefit but for this paragraph and (ii) to immediately pay or transfer to the Security Agent any payment or distribution or benefit of Security received by it contrary to this paragraph or as otherwise directed by the Security Agent under this paragraph.

---

**11. Release of Pledged Assets**

- (a) Subject to Clause 12 (*Reinstatement and avoidance of payments*) below, at the request and at the cost of the Pledgor, the Security Agent shall release and discharge the Pledged Assets from the Pledge upon full and final discharge of the Secured Obligations or as otherwise expressly permitted under the Finance Documents.
- (b) Upon release and discharge pursuant to paragraph (a) of this Clause, the Pledge created pursuant to this Agreement shall automatically terminate and the Pledged Assets then remaining and not previously applied against the Secured Obligations shall be released and returned by the Security Agent (or such other Pledgee, as the case may be) to the Pledgor (all at the sole cost of the Pledgor).
- (c) The Security Agent and the other Pledgees will not make or shall not be deemed to have made any representation or warranty, whether express or implied, with respect to any Pledged Assets so delivered, except that any such Pledged Assets shall be delivered to the Pledgor free and clear of any encumbrance or other third party right granted by the Security Agent or any other Pledgee.

---

**12. Reinstatement and avoidance of payments**

If any payment in respect of Secured Obligations, whereupon the Security Agent discharged the Security (or any part thereof) expressed to be created pursuant to this Agreement, is avoided or reduced as a result of insolvency or any similar event:

- (a) the liability of the Pledgor and the Security granted under this Agreement shall, to the extent legally permitted, continue as if the payment, discharge, avoidance or reduction had not occurred and such amount shall not be considered to have been irrevocably paid and the liability of the Pledgor and the Security expressed to be created under this Agreement shall be reinstated and continue as if the payment, discharge, avoidance or reduction had not occurred; and
- (b) the Pledgor shall pledge, return and deliver (as the case may be) to the Security Agent any Pledged Asset, including, for the avoidance of doubt, any proceeds from the collection or disposal of and any other substitutes

for the Pledged Assets, as if the repayment, discharge, avoidance or reduction had not occurred.

---

**13. Miscellaneous**

**13.1. Costs and expenses**

All costs and expenses (including legal fees) arising out of or in connection with the preparation, execution, amendment and enforcement of, or any performance under, this Agreement shall be borne in accordance with the terms of the Facility Agreement.

**13.2. Waivers and amendment**

- (a) No failure on the part of the Security Agent or any other Pledgee to exercise, or delay on its part in exercising, any Collateral Right shall operate as a waiver thereof, nor shall any single or partial exercise of a Collateral Right preclude any further or other exercise of that or any other Collateral Right.
- (b) Any amendment or waiver of this Agreement or any provision of this Agreement (including this Clause 13.2 (*Waivers and amendment*)) shall only be binding if agreed in writing by all Parties.

**13.3. Assignment or transfer**

- (a) The Pledgor may not transfer or assign this Agreement or any rights or obligations hereunder without the prior written consent of the Security Agent.
- (b) If a successor of the Security Agent is appointed pursuant to the Finance Documents, the existing Security Agent may assign and transfer by way of written agreement all of its rights and obligations hereunder (including by way of transfer of agreement (*Vertragsübernahme/-übertragung*)) to its successor without further consent of the Pledgor. The Pledgor herewith irrevocably and unconditionally agrees in advance to such transfer and assignment and to recognise any such successor as



new Security Agent in substitution of the retiring Security Agent, and to do all acts (at its own cost) necessary or useful for the successor Security Agent to be recognised by third parties as new Security Agent hereunder (including countersigning the written agreement of assignment and transfer).

#### **13.4. Notices**

Any notice, request or other communication under this Agreement shall be given in accordance with the provisions of section 9.1 (*Notices*) of the Facility Agreement which shall apply to this Agreement *mutatis mutandis*.

#### **13.5. Severability**

If any provision of this Agreement is or becomes illegal, invalid or unenforceable in any jurisdiction, this shall not affect or impair (i) the validity or enforceability in that jurisdiction of any other provision of this Agreement or (ii) the validity or enforceability in any other jurisdiction of that or any other provision of this Agreement, and the Parties will negotiate in good faith to replace the relevant provision by another provision reflecting as closely as possible the original intention and purpose of the Parties.

#### **13.6. Counterparts**

This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

---

#### **14. Law and jurisdiction**

- (a) This Agreement shall in all respects, including, without limitation, all the rights in rem aspects, be governed by and construed in accordance with the substantive laws of Switzerland (to the exclusion of conflict of law rules).
- (b) Each Party submits to the exclusive jurisdiction of the courts of the city of Zurich, Switzerland (including a dispute regarding the existence, validity or termination of this Agreement or any non-contractual


obligation arising out of or in connection with this Agreement). The Security Agent and each other Pledgee reserves the right to bring an action against the Pledgor at its place of domicile or before any other competent court.

[SIGNATURE PAGE FOLLOWS]

Signatures

ADC THERAPEUTICS SA

Pledgor



Name: Chris Martin  
Title: CEO

Name: Michael Forer  
Title: Vice Chairman & EVP

DEERFIELD PARTNERS, L.P.

Security Agent

for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Secured Parties

By: Deerfield Mgmt, L.P.,  
its General Partner

By: J.E. Flynn Capital, LLC,  
its General Partner

By: \_\_\_\_\_

Name: David J. Clark

Title: Authorized Signatory


---

**Signatures**

---

**ADC THERAPEUTICS SA**

**Pledgor**



---

Name: Chris Martin  
Title: CEO

Name: Michael Forer  
Title: Vice Chairman & EVP

---

**DEERFIELD PARTNERS, L.P.**

**Security Agent**

for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Secured Parties

By: Deerfield Mgmt, L.P.,  
its General Partner

By: J.E. Flynn Capital, LLC,  
its General Partner

By: \_\_\_\_\_

Name: David J. Clark

Title: Authorized Signatory

**Signatures**

**ADC THERAPEUTICS SA**

**Pledgor**

Name:

Name:

Title:

Title:

**DEERFIELD PARTNERS, L.P.**


**Security Agent**

for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Secured Parties

By: Deerfield Mgmt, L.P.,  
its General Partner

By: J.E. Flynn Capital, LLC,  
its General Partner

By:



Name: David J. Clark

Title: Authorized Signatory

---

**Schedule 1: Existing Intellectual Property**

---

**A. Copyrights**

[None as of the date hereof.] Homburger to confirm

## B. Patents

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                                 | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 1 AU (SGNAT-101AU1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 2013328619      | 11/10/2013       | 2013328619        | 02/03/2017 | Australia    |
| Patent 1 BR (SGNAT-101BR1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Pending | BR1120150081738 | 11/10/2013       |                   |            | Brazil       |
| Patent 1 CA (SGNAT-101CA1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 2887894         | 11/10/2013       | 2887894           | 29/10/2019 | Canada       |
| Patent 1 CN (SGNAT-101CN1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 201380065405.7  | 11/10/2013       | ZL201380065405.7  | 05/03/2019 | China        |
| Patent 1 IN (SGNAT-101IN1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Pending | 1069/MUMNP/2015 | 11/10/2013       |                   |            | India        |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                                 | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-------------------------------------------------------|---------|------------------|------------------|-------------------|------------|-----------------|
| Patent 1 JP (SGNAT-101JP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 2015-536162      | 11/10/2013       | 6270859           | 12/01/2018 | Japan           |
| Patent 1 MX (SGNAT-101MX1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | MX/A/2015/004416 | 11/10/2013       | 364326            | 23/04/2019 | Mexico          |
| Patent 1 NZ (SGNAT-101NZ1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 707486           | 11/10/2013       | 707486            | 04/01/2019 | New Zealand     |
| Patent 1 ZA (SGNAT-101ZA1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 2015/02437       | 11/10/2013       | 2015/02437        | 25/10/2017 | South Africa    |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0       | 11/10/2013       | 2906253           | 01/08/2018 | European Patent |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0       | 11/10/2013       |                   | 01/08/2018 | Albania         |



IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                                 | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction   |
|----------------------------|---------------------|-------------------|-------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|----------------|
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Austria        |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Belgium        |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       |                   | 01/08/2018 | Bulgaria       |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Switzerland    |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       |                   | 01/08/2018 | Cyprus (S)     |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Czech Republic |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                                 | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 602013041276.6    | 01/08/2018 | Germany      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Denmark      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Estonia      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2690067           | 01/08/2018 | Spain        |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Finland      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | France       |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                                 | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 3097620           | 01/08/2018 | Greece       |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | P20181646         | 01/08/2018 | Croatia      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | E041274           | 01/08/2018 | Hungary      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Ireland      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Iceland      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 502018000033160   | 01/08/2018 | Italy        |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                                 | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Lithuania       |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Luxembourg      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Latvia          |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Monaco          |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | North Macedonia |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Malta           |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                                 | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Netherlands  |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Norway       |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Poland       |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Portugal     |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Romania      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 57694             | 01/08/2018 | Serbia       |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                                 | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Sweden          |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | Slovenia        |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 29021             | 01/08/2018 | Slovak Republic |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | 2906253           | 01/08/2018 | San Marino      |
| Patent 1 EP (SGNAT-101EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13795435.0      | 11/10/2013       | TR201815418T4     | 01/08/2018 | Turkey          |
| Patent 2 EP (SGNAT-102EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13785372.7      | 11/10/2013       | 2906250           | 30/05/2018 | European Patent |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 2 EP (SGNAT-102EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13785372.7      | 11/10/2013       | 2906250           | 30/05/2018 | Switzerland  |
| Patent 2 EP (SGNAT-102EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13785372.7      | 11/10/2013       | 602013038266.2    | 30/05/2018 | Germany      |
| Patent 2 EP (SGNAT-102EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13785372.7      | 11/10/2013       | 2680153           | 30/05/2018 | Spain        |
| Patent 2 EP (SGNAT-102EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13785372.7      | 11/10/2013       | 2906250           | 30/05/2018 | France       |
| Patent 2 EP (SGNAT-102EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13785372.7      | 11/10/2013       | 2906250           | 30/05/2018 | Ireland      |
| Patent 2 EP (SGNAT-102EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13785372.7      | 11/10/2013       | 502018000025660   | 30/05/2018 | Italy        |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| Patent 2 EP (SGNAT-102EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | Granted | 13785372.7       | 11/10/2013       | 2906250           | 30/05/2018 | Netherlands  |
| Patent 4 AU (SGNAT-104AU1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 2013328623       | 11/10/2013       | 2013328623        | 30/03/2017 | Australia    |
| Patent 4 BR (SGNAT-104BR1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Pending | BR 1120150081746 | 11/10/2013       |                   |            | Brazil       |
| Patent 4 CA (SGNAT-104CA1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 2887895          | 11/10/2013       | 2887895           | 29/10/2019 | Canada       |
| Patent 4 CN (SGNAT-104CN1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 201380065424.X   | 11/10/2013       | ZL201380065424.X  | 30/03/2018 | China        |
| Patent 4 IN (SGNAT-104IN1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Pending | 1090/MUMNP/2015  | 11/10/2013       |                   |            | India        |



IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|------------------|------------------|-------------------|------------|-----------------|
| Patent 4 JP (SGNAT-104JP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 2015-536164      | 11/10/2013       | 6392763           | 31/08/2018 | Japan           |
| Patent 4 MX (SGNAT-104MX1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | MX/A/2015/004449 | 11/10/2013       | 364329            | 23/04/2019 | Mexico          |
| Patent 4 NZ (SGNAT-104NZ1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 707534           | 11/10/2013       | 707534            | 04/12/2018 | New Zealand     |
| Patent 4 ZA (SGNAT-104ZA1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 2015/02428       | 11/10/2013       | 2015/02428        | 25/10/2017 | South Africa    |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2       | 11/10/2013       | 2906298           | 03/10/2018 | European Patent |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2       | 11/10/2013       | 843               | 03/10/2018 | Albania         |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction   |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|----------------|
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Austria        |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Belgium        |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       |                   | 03/10/2018 | Bulgaria       |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Switzerland    |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | CY1121349         | 03/10/2018 | Cyprus (S)     |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Czech Republic |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 602013044545.1    | 03/10/2018 | Germany      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Denmark      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Estonia      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2703151           | 03/10/2018 | Spain        |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Finland      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | France       |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 3098343           | 03/10/2018 | Greece       |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | P20182129         | 03/10/2018 | Croatia      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | E042731           | 03/10/2018 | Hungary      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Ireland      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Iceland      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 502019000000922   | 03/10/2018 | Italy        |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Lithuania       |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Luxembourg      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Latvia          |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Monaco          |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | North Macedonia |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Malta           |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Netherlands  |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Norway       |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Poland       |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Portugal     |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Romania      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 57964             | 03/10/2018 | Serbia       |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Sweden          |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | Slovenia        |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | E 29638           | 03/10/2018 | Slovak Republic |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | 2906298           | 03/10/2018 | San Marino      |
| Patent 4 EP (SGNAT-104EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785831.2      | 11/10/2013       | Tv 2018 18821 T4  | 03/10/2018 | Turkey          |
| Patent 6 AU (SGNAT-106AU1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 2013328625      | 11/10/2013       | 2013328625        | 30/03/2017 | Australia       |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| Patent 6 BR (SGNAT-106BR1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | BR1120150082327  | 11/10/2013       |                   |            | Brazil       |
| Patent 6 CA (SGNAT-106CA1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 2887897          | 11/10/2013       | 2887897           | 18/02/2020 | Canada       |
| Patent 6 CN (SGNAT-106CN1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 201380065423.5   | 11/10/2013       | ZL201380065423.5  | 01/06/2018 | China        |
| Patent 6 IN (SGNAT-106IN1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 1094/MUMNP/2015  | 11/10/2013       |                   |            | India        |
| Patent 6 JP (SGNAT-106JP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 2015-536165      | 11/10/2013       | 6392764           | 31/08/2018 | Japan        |
| Patent 6 MX (SGNAT-106MX1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | MX/A/2015/004421 | 11/10/2013       | 364328            | 23/04/2019 | Mexico       |



IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 6 NZ (SGNAT-106NZ1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 707543          | 11/10/2013       | 707543            | 04/01/2019 | New Zealand     |
| Patent 6 ZA (SGNAT-106ZA1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 2015/02523      | 11/10/2013       | 2015/02523        | 27/09/2017 | South Africa    |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | European Patent |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 7628              | 21/03/2018 | Albania         |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Austria         |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Belgium         |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction   |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|----------------|
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       |                   | 21/03/2018 | Bulgaria       |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Switzerland    |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | CY1120327         | 21/03/2018 | Cyprus (S)     |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Czech Republic |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 602013034757.3    | 21/03/2018 | Germany        |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Denmark        |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Estonia      |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2670937           | 21/03/2018 | Spain        |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Finland      |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | France       |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 3096098           | 21/03/2018 | Greece       |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | P20180945         | 21/03/2018 | Croatia      |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | E039329           | 21/03/2018 | Hungary      |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Ireland      |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Iceland      |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 5020180000017531  | 21/03/2018 | Italy        |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Lithuania    |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Luxembourg   |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Latvia          |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Monaco          |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       |                   | 21/03/2018 | North Macedonia |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Malta           |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Netherlands     |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Norway          |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Poland       |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Portugal     |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Romania      |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 57104             | 21/03/2018 | Serbia       |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Sweden       |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | Slovenia     |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 27632             | 21/03/2018 | Slovak Republic |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | 2906296           | 21/03/2018 | San Marino      |
| Patent 6 EP (SGNAT-106EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785373.5      | 11/10/2013       | TR201808051T4     | 21/03/2018 | Turkey          |
| Patent 7 EP (SGNAT-107EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785374.3      | 11/10/2013       | 2906297           | 06/12/2017 | European Patent |
| Patent 7 EP (SGNAT-107EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785374.3      | 11/10/2013       | 2906297           | 06/12/2017 | Switzerland     |
| Patent 7 EP (SGNAT-107EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 13785374.3      | 11/10/2013       | 602013030499.8    | 06/12/2017 | Germany         |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 7 EP (SGNAT-107EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 13785374.3      | 11/10/2013       | 2660029           | 06/12/2017 | Spain        |
| Patent 7 EP (SGNAT-107EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 13785374.3      | 11/10/2013       | 2906297           | 06/12/2017 | France       |
| Patent 7 EP (SGNAT-107EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 13785374.3      | 11/10/2013       | 2906297           | 06/12/2017 | Ireland      |
| Patent 7 EP (SGNAT-107EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 13785374.3      | 11/10/2013       | 502018000007476   | 06/12/2017 | Italy        |
| Patent 7 EP (SGNAT-107EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 13785374.3      | 11/10/2013       | 2906297           | 06/12/2017 | Netherlands  |
| Patent 9 AU (SGNAT-109AU1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 2013328628      | 11/10/2013       | 2013328628        | 30/03/2017 | Australia    |



IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| Patent 9 BR (SGNAT-109BR1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Pending | BR1120150082386  | 11/10/2013       |                   |            | Brazil       |
| Patent 9 CA (SGNAT-109CA1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 2887899          | 11/10/2013       | 2887899           | 31/03/2020 | Canada       |
| Patent 9 CN (SGNAT-109CN1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 201380065412.7   | 11/10/2013       | ZL201380065412.7  | 25/01/2019 | China        |
| Patent 9 IN (SGNAT-109IN1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Pending | 1115/MUMNP/2015  | 11/10/2013       |                   |            | India        |
| Patent 9 JP (SGNAT-109JP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 2015-536166      | 11/10/2013       | 6392765           | 31/08/2018 | Japan        |
| Patent 9 MX (SGNAT-109MX1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | MX/A/2015/004420 | 11/10/2013       | 364327            | 23/04/2019 | Mexico       |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 9 NZ (SGNAT-109NZ1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 707490          | 11/10/2013       | 707490            | 04/01/2019 | New Zealand     |
| Patent 9 ZA (SGNAT-109ZA1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 2015/02524      | 11/10/2013       | 2015/02524        | 30/05/2018 | South Africa    |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | European Patent |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 7082              | 27/09/2017 | Albania         |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Austria         |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Belgium         |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction   |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|----------------|
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       |                   | 27/09/2017 | Bulgaria       |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Switzerland    |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | CY1119782         | 27/09/2017 | Cyprus (S)     |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Czech Republic |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 602013027209.3    | 27/09/2017 | Germany        |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Denmark        |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Estonia      |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2649990           | 27/09/2017 | Spain        |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Finland      |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | France       |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 3094563           | 27/09/2017 | Greece       |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | P20171916         | 27/09/2017 | Croatia      |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | E035694           | 27/09/2017 | Hungary      |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Ireland      |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Iceland      |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 502017000149754   | 27/09/2017 | Italy        |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Lithuania    |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Luxembourg   |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Latvia          |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Monaco          |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       |                   |            | North Macedonia |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Malta           |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       |                   |            |                 |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Netherlands     |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       |                   |            | Norway          |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|----------------------------|---------------------|-------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Poland       |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Portugal     |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Romania      |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 56520             | 27/09/2017 | Serbia       |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Sweden       |
| Patent 9 EP (SGNAT-109EP1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | Slovenia     |

IP Pledge Agreement

| Internal Reference          | 1st Applicant       | 2nd Applicant       | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|-----------------------------|---------------------|---------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 9 EP (SGNAT-109EP1)  | ADC Therapeutics SA | MedImmune Limited   | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | E26100T3          | 27/09/2017 | Slovak Republic |
| Patent 9 EP (SGNAT-109EP1)  | ADC Therapeutics SA | MedImmune Limited   | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | 2906251           | 27/09/2017 | San Marino      |
| Patent 9 EP (SGNAT-109EP1)  | ADC Therapeutics SA | MedImmune Limited   | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Granted | 13786186.0      | 11/10/2013       | TR201720163T4     | 27/09/2017 | Turkey          |
| Patent 13 EP (SGNAT-113EP1) | MedImmune Limited   | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 14787022.4      | 10/10/2014       | 3054983           | 20/03/2019 | European Patent |
| Patent 13 EP (SGNAT-113EP1) | MedImmune Limited   | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 14787022.4      | 10/10/2014       | 3054983           | 20/03/2019 | Switzerland     |
| Patent 13 EP (SGNAT-113EP1) | MedImmune Limited   | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Granted | 14787022.4      | 10/10/2014       | 602014043311.1    | 20/03/2019 | Germany         |



IP Pledge Agreement

| Internal Reference          | 1st Applicant     | 2nd Applicant       | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|-----------------------------|-------------------|---------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 13 EP (SGNAT-113EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787022.4      | 10/10/2014       | 3054983           | 20/03/2019 | France          |
| Patent 13 EP (SGNAT-113EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787022.4      | 10/10/2014       | 3054983           | 20/03/2019 | Ireland         |
| Patent 13 EP (SGNAT-113EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787022.4      | 10/10/2014       | 3054983           | 20/03/2019 | Netherlands     |
| Patent 15 EP (SGNAT-115EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787024.0      | 10/10/2014       | 3054985           | 26/12/2018 | European Patent |
| Patent 15 EP (SGNAT-115EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787024.0      | 10/10/2014       | 3054985           | 26/12/2018 | Switzerland     |
| Patent 15 EP (SGNAT-115EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787024.0      | 10/10/2014       | 602014038719.5    | 26/12/2018 | Germany         |

IP Pledge Agreement

| Internal Reference          | 1st Applicant     | 2nd Applicant       | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|-----------------------------|-------------------|---------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|-----------------|
| Patent 15 EP (SGNAT-115EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787024.0      | 10/10/2014       | 3054985           | 26/12/2018 | France          |
| Patent 15 EP (SGNAT-115EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787024.0      | 10/10/2014       | 3054985           | 26/12/2018 | Ireland         |
| Patent 15 EP (SGNAT-115EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787024.0      | 10/10/2014       | 3054985           | 26/12/2018 | Netherlands     |
| Patent 17 EP (SGNAT-117EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787025.7      | 10/10/2014       | 3054986           | 20/03/2019 | European Patent |
| Patent 17 EP (SGNAT-117EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787025.7      | 10/10/2014       | 3054986           | 20/03/2019 | Switzerland     |
| Patent 17 EP (SGNAT-117EP1) | MedImmune Limited | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787025.7      | 10/10/2014       | 602015043313.8    | 20/03/2019 | Germany         |

IP Pledge Agreement

| Internal Reference          | 1st Applicant       | 2nd Applicant       | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|-----------------------------|---------------------|---------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| Patent 17 EP (SGNAT-117EP1) | MedImmune Limited   | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787025.7      | 10/10/2014       | 3054986           | 20/03/2019 | France                   |
| Patent 17 EP (SGNAT-117EP1) | MedImmune Limited   | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787025.7      | 10/10/2014       | 3054986           | 20/03/2019 | Ireland                  |
| Patent 17 EP (SGNAT-117EP1) | MedImmune Limited   | ADC Therapeutics SA | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 14787025.7      | 10/10/2014       | 3054986           | 20/03/2019 | Netherlands              |
| Patent 25 EP (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited   | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 15801398.7      | 25/11/2015       |                   |            | European Patent          |
| Patent 25 WO (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited   | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 15/529622       | 25/11/2015       |                   |            | United States of America |
| Patent 25 WO (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited   | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 2015352545      | 25/11/2015       |                   |            | Australia                |

IP Pledge Agreement

| Internal Reference          | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|-----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent 25 WO (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | BR112017011110  | 25/11/2015       |                   |            | Brazil       |
| Patent 25 WO (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 2968447         | 25/11/2015       |                   |            | Canada       |
| Patent 25 CN (SGNAT-125CN1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 201580072448.7  | 25/11/2015       |                   |            | China        |
| Patent 25 WO (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 201727016706    | 25/11/2015       |                   |            | India        |
| Patent 25 WO (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 2017-546038     | 25/11/2015       |                   |            | Japan        |

IP Pledge Agreement

| Internal Reference          | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction     |
|-----------------------------|---------------------|-------------------|-------------------------------------------|---------|------------------|------------------|-------------------|------------|------------------|
| Patent 25 WO (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 10-2017-7014301  | 25/11/2015       |                   |            | South Korea      |
| Patent 25 WO (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | MX/A/2017/006770 | 25/11/2015       |                   |            | Mexico           |
| Patent 25 WO (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 731782           | 25/11/2015       |                   |            | New Zealand      |
| Patent 25 ZA (SGNAT-125WO1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 2017/04297       | 25/11/2015       |                   |            | South Africa     |
| Patent 26 EP (SGNAT-126WO1) | ADC Therapeutics SA | MedImmune Limited | DIAGNOSTIC TEST INVOLVING ANTI-CD25-ADC   | Pending | 15802044.6       | 25/11/2015       |                   |            | European Patent  |
| Patent 26 US                | ADC                 | MedImmune         | DIAGNOSTIC TEST INVOLVING                 | Pending | 15/571969        | 25/11/2015       |                   |            | United States of |

IP Pledge Agreement

| Internal Reference               | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|----------------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| (SGNAT-126WO1)                   | Therapeutics SA     | Limited           | ANTI-CD25-ADC                             |         |                 |                  |                   |            | America                  |
| Patent 45 EP (SGNAT-145WO1)      | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 15802045.3      | 25/11/2015       |                   |            | European Patent          |
| Patent 45 US conf (SGNAT-145US2) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 16806910        | 25/11/2015       |                   |            | United States of America |
| Patent 55 EP (SGAT-155EP-1)      | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 18704956.4      | 08/02/2018       |                   |            | European Patent          |
| Patent 55 AU (SGAT-155AU-1)      | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Granted | 2018217926      | 08/02/2018       | 2018217926        | 16/01/2020 | Australia                |
| Patent 55 BR (SGAT-155BR-1)      | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | BR1120190163735 | 08/02/2018       |                   |            | Brazil                   |
| Patent 55 CA                     | ADC                 | MedImmune         | PYRROLOBENZODIAZEPINE-                    | Granted | 3047683         | 08/02/2018       | 3047683           | 10/03/2020 | Canada                   |

IP Pledge Agreement

| Internal Reference          | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|-----------------------------|---------------------|-------------------|-------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| (SGAT-155CA1)               | Therapeutics SA     | Limited           | ANTIBODY CONJUGATES                       |         |                  |                  |                   |            |              |
| Patent 55 CN (SGAT-155CN-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 201880010619.7   | 08/02/2018       |                   |            | China        |
| Patent 55 IN (SGAT-155IN-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 201927032948     | 08/02/2018       |                   |            | India        |
| Patent 55 JP (SGAT-155JP-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 2019-542659      | 08/02/2018       |                   |            | Japan        |
| Patent 55 KR (SGAT-155KR-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 10-2019-7023785  | 08/02/2018       |                   |            | South Korea  |
| Patent 55 MX (SGAT-155MX-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | MX/a/2019/009428 | 08/02/2018       |                   |            | Mexico       |
| Patent 55 NZ (SGAT-155NZ-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 754810           | 08/02/2018       |                   |            | New Zealand  |

IP Pledge Agreement

| Internal Reference          | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|-----------------------------|---------------------|-------------------|-------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| 155NZ-1)                    | SA                  |                   |                                           |         |                 |                  |                   |            |                          |
| Patent 55 ZA (SGAT-155ZA-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 2019/04353      | 08/02/2018       |                   |            | South Africa             |
| Patent 55 HK (SGAT-155HK-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 62020002499.5   | 08/02/2018       |                   |            | Hong Kong                |
| Patent 56 - 63 & 103 EP     | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY                       | Pending | 18721976.1      | 20/04/2018       |                   |            | European Patent          |
| Patent 56 - 63 & 103 US     | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY                       | Pending | 16/605701       | 20/04/2018       |                   |            | United States of America |
| Patent 56 - 63 & 103 AU     | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY                       | Pending | 2018253951      | 20/04/2018       |                   |            | Australia                |
| Patent 56 - 63 & 103 BR     | ADC Therapeutics    | MedImmune Limited | COMBINATION THERAPY                       | Pending | BR1120190218220 | 20/04/2018       |                   |            | Brazil                   |



IP Pledge Agreement

| Internal Reference      | 1st Applicant       | 2nd Applicant     | Title               | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|-------------------------|---------------------|-------------------|---------------------|---------|------------------|------------------|-------------------|------------|--------------|
| Patent 56 - 63 & 103 CA | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY | Pending | 3057749          | 20/04/2018       |                   |            | Canada       |
| Patent 56 - 63 & 103 CN | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY | Pending | 201880038974.5   | 20/04/2018       |                   |            | China        |
| Patent 56 - 63 & 103 IN | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY | Pending | 201927036586     | 20/04/2018       |                   |            | India        |
| Patent 56 - 63 & 103 JP | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY | Pending | 2019-556889      | 20/04/2018       |                   |            | Japan        |
| Patent 56 - 63 & 103 MX | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY | Pending | MX/A/2019/012462 | 20/04/2018       |                   |            | Mexico       |
| Patent 56 - 63 & 103 NZ | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY | Pending | 756733           | 20/04/2018       |                   |            | New Zealand  |

IP Pledge Agreement

| Internal Reference      | 1st Applicant       | 2nd Applicant     | Title                                                          | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|-------------------------|---------------------|-------------------|----------------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| Patent 56 - 63 & 103 ZA | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY                                            | Pending | 2019/05719      | 20/04/2018       |                   |            | South Africa             |
| Patent 56 - 63 & 103 KR | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY                                            | Pending | 10-2019-7033821 | 20/04/2018       |                   |            | South Korea              |
| Patent 64 - 71 EP       | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE | Pending | 18719542.5      | 20/04/2018       |                   |            | European Patent          |
| Patent 64 - 71 US       | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE | Pending | 16/605708       | 20/04/2018       |                   |            | United States of America |
| Patent 64 - 71 AU       | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE | Pending | 2018253950      | 20/04/2018       |                   |            | Australia                |
| Patent 64 - 71 BR       | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE | Pending | BR1120190216804 | 20/04/2018       |                   |            | Brazil                   |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant     | Title                                                           | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|--------------------|---------------------|-------------------|-----------------------------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| Patent 64 - 71 CA  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY - DRUG CONJUGATE | Pending | 3057744          | 20/04/2018       |                   |            | Canada       |
| Patent 64 - 71 CN  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY - DRUG CONJUGATE | Pending | 201880029617.2   | 20/04/2018       |                   |            | China        |
| Patent 64 - 71 IN  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY - DRUG CONJUGATE | Pending | 201927036583     | 20/04/2018       |                   |            | India        |
| Patent 64 - 71 JP  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY - DRUG CONJUGATE | Pending | 2019-556813      | 20/04/2018       |                   |            | Japan        |
| Patent 64 - 71 MX  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY - DRUG CONJUGATE | Pending | MX/A/2019/012465 | 20/04/2018       |                   |            | Mexico       |
| Patent 64 - 71 NZ  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY - DRUG CONJUGATE | Pending | 756731           | 20/04/2018       |                   |            | New Zealand  |

IP Pledge Agreement

| Internal Reference      | 1st Applicant       | 2nd Applicant     | Title                                                         | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|-------------------------|---------------------|-------------------|---------------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| Patent 64 - 71 ZA       | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE | Pending | 2019/05728      | 20/04/2018       |                   |            | South Africa             |
| Patent 64 - 71 KR       | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE | Pending | 10-2019-7032525 | 20/04/2018       |                   |            | South Korea              |
| Patent 80 - 86 EP       | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-PSMA ANTIBODY-DRUG CONJUGATE | Pending | 18719163.0      | 20/04/2018       |                   |            | European Patent          |
| Patent 80 - 86 US       | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-PSMA ANTIBODY-DRUG CONJUGATE | Pending | 16/605710       | 20/04/2018       |                   |            | United States of America |
| Patent 87-95 US[bypass] | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE  | Granted | 16/197891       | 20/04/2018       | 10544223          | 28/01/2020 | United States of America |
| Patent 87 - 95 EP       | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE  | Pending | 18719162.2      | 20/04/2018       |                   |            | European Patent          |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant     | Title                                                        | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|-------------------|--------------------------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------------------|
| Patent 87 - 95 US  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | 16/605692        | 20/04/2018       |                   |            | United States of America |
| Patent 87 - 95 AU  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | 2018253948       | 20/04/2018       |                   |            | Australia                |
| Patent 87 - 95 BR  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | BR 1120190218807 | 20/04/2018       |                   |            | Brazil                   |
| Patent 87 - 95 CA  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | 3057748          | 20/04/2018       |                   |            | Canada                   |
| Patent 87 - 95 CN  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | 201880025195.1   | 20/04/2018       |                   |            | China                    |
| Patent 87 - 95 IN  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | 201927036584     | 20/04/2018       |                   |            | India                    |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant     | Title                                                        | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction    |
|--------------------|---------------------|-------------------|--------------------------------------------------------------|---------|------------------|------------------|-------------------|------------|-----------------|
| Patent 87 - 95 JP  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | 2019-556986      | 20/04/2018       |                   |            | Japan           |
| Patent 87 - 95 MX  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | MX/A/2019/012464 | 20/04/2018       |                   |            | Mexico          |
| Patent 87 - 95 NZ  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | 756730           | 20/04/2018       |                   |            | New Zealand     |
| Patent 87 - 95 ZA  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | 2019/05727       | 20/04/2018       |                   |            | South Africa    |
| Patent 87 - 95 KR  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | Pending | 10-2019-7030286  | 20/04/2018       |                   |            | South Korea     |
| Patent 96 & 99 EP  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC    | Pending | 18732040.3       | 14/06/2018       |                   |            | European Patent |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant     | Title                                                     | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|-------------------|-----------------------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------------------|
| Patent 96 & 99 US  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC | Pending | 16/622663        | 14/06/2018       |                   |            | United States of America |
| Patent 96 & 99 AU  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC | Pending | 2018285455       | 14/06/2018       |                   |            | Australia                |
| Patent 96 & 99 BR  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC | Pending | BR 1120190264981 | 14/06/2018       |                   |            | Brazil                   |
| Patent 96 & 99 CA  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC | Pending | 3064681          | 14/06/2018       |                   |            | Canada                   |
| Patent 96 & 99 JP  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC | Pending | 2019-569364      | 14/06/2018       |                   |            | Japan                    |
| Patent 96 & 99 MX  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC | Pending | MX/a/2019/014923 | 14/06/2018       |                   |            | Mexico                   |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant     | Title                                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|-------------------|-----------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| Patent 96 & 99 NZ  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC | Pending | 759150          | 14/06/2018       |                   |            | New Zealand              |
| Patent 96 & 99 ZA  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC | Pending | 2019/07611      | 14/06/2018       |                   |            | South Africa             |
| Patent 96 & 99 KR  | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC | Pending | 10-2020-7001219 | 14/06/2018       |                   |            | South Korea              |
| Patents 97 & 98 EP | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC | Pending | 18732041.1      | 14/06/2018       |                   |            | European Patent          |
| Patents 97 & 98 US | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC | Pending | 16/622649       | 14/06/2018       |                   |            | United States of America |
| Patents 97 & 98 AU | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC | Pending | 2018285562      | 14/06/2018       |                   |            | Australia                |



IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant     | Title                                                     | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|--------------------|---------------------|-------------------|-----------------------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| Patents 97 & 98 BR | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC | Pending | BR1120190265643  | 14/06/2018       |                   |            | Brazil       |
| Patents 97 & 98 CA | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC | Pending | 3064804          | 14/06/2018       |                   |            | Canada       |
| Patents 97 & 98 JP | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC | Pending | 2019-569479      | 14/06/2018       |                   |            | Japan        |
| Patents 97 & 98 MX | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIME FOR THE ADMINISTRATION OF AN ANTI-CD ADC    | Pending | MX/a/2019/015042 | 14/06/2018       |                   |            | Mexico       |
| Patents 97 & 98 NZ | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC | Pending | 759283           | 14/06/2018       |                   |            | New Zealand  |
| Patents 97 & 98 ZA | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC | Pending | 2019/07613       | 14/06/2018       |                   |            | South Africa |

IP Pledge Agreement

| Internal Reference                    | 1st Applicant       | 2nd Applicant     | Title                                                     | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|---------------------------------------|---------------------|-------------------|-----------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| Patents 97 & 98 KR                    | ADC Therapeutics SA | MedImmune Limited | DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC | Pending | 10-2019-7037482 | 14/06/2018       |                   |            | South Korea              |
| Patent 102/104/105 EP (SGAT-1102WO-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES                 | Pending | 18706437.3      | 08/02/2018       |                   |            | European Patent          |
| Patent 102/104/105 US (SGAT-1102WO-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES                 | Pending | 16484313        | 08/02/2018       |                   |            | United States of America |
| Patent 102/104/105 AU (SGAT-1102WO-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES                 | Granted | 2018219654      | 08/02/2018       | 2018219654        | 23/01/2020 | Australia                |
| Patent 102/104/105 BR (SGAT-1102WO-1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES                 | Pending | BR1120190164200 | 08/02/2018       |                   |            | Brazil                   |

IP Pledge Agreement

| Internal Reference                              | 1st Applicant             | 2nd Applicant        | Title                                         | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|-------------------------------------------------|---------------------------|----------------------|-----------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------|
| Patent<br>102/104/105<br>CA (SGAT-<br>1102WO-1) | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | PYRROLOBENZODIAZEPINE-<br>ANTIBODY CONJUGATES | Pending | 3047686         | 08/02/2018       |                   |            | Canada       |
| Patent<br>102/104/105<br>CN (SGAT-<br>1102WO-1) | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | PYRROLOBENZODIAZEPINE-<br>ANTIBODY CONJUGATES | Pending | 201880009386.9  | 08/02/2018       |                   |            | China        |
| Patent<br>102/104/105<br>IN (SGAT-<br>1102WO-1) | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | PYRROLOBENZODIAZEPINE-<br>ANTIBODY CONJUGATES | Pending | 201927032945    | 08/02/2018       |                   |            | India        |
| Patent<br>102/104/105<br>JP (SGAT-<br>1102WO-1) | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | PYRROLOBENZODIAZEPINE-<br>ANTIBODY CONJUGATES | Pending | 2019-542213     | 08/02/2018       |                   |            | Japan        |
| Patent<br>102/104/105<br>KR (SGAT-<br>1102WO-1) | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | PYRROLOBENZODIAZEPINE-<br>ANTIBODY CONJUGATES | Pending | 10-2019-7023786 | 08/02/2018       |                   |            | South Korea  |

IP Pledge Agreement

| Internal Reference                              | 1st Applicant             | 2nd Applicant        | Title                                                              | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|-------------------------------------------------|---------------------------|----------------------|--------------------------------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| Patent<br>102/104/105<br>MX (SGAT-<br>1102WO-1) | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | PYRROLOBENZODIAZEPINE-<br>ANTIBODY CONJUGATES                      | Pending | MX/a/2019/009427 | 08/02/2018       |                   |            | Mexico       |
| Patent<br>102/104/105<br>NZ (SGAT-<br>1102WO-1) | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | PYRROLOBENZODIAZEPINE-<br>ANTIBODY CONJUGATES                      | Pending | 754811           | 08/02/2018       |                   |            | New Zealand  |
| Patent<br>102/104/105<br>ZA (SGAT-<br>1102WO-1) | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | PYRROLOBENZODIAZEPINE-<br>ANTIBODY CONJUGATES                      | Pending | 2019/04269       | 08/02/2018       |                   |            | South Africa |
| Patent<br>102/104/105                           | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | PYRROLOBENZODIAZEPINE-<br>ANTIBODY CONJUGATES                      | Pending | 62020002383.1    | 08/02/2018       |                   |            | Hong Kong    |
| 11504-035                                       | ADC<br>Therapeutics<br>SA |                      | POLYNUCLEOTIDES AND<br>POLYPEPTIDE SEQUENCES<br>INVOLVED IN CANCER | Issued  | 2007262635       | 6/22/2017        | 2007262635        | 1/8/2015   | Australia    |
| 11504-036                                       | ADC                       |                      | POLYNUCLEOTIDES AND                                                | Issued  | 2,655,933        | 6/22/2017        | 2655933           | 9/9/2014   | Canada       |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                        | Status | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|---------------|--------------------------------------------------------------|--------|-----------------|------------------|-------------------|------------|--------------------------|
|                    | Therapeutics SA     |               | POLYPEPTIDE SEQUENCES INVOLVED IN CANCER                     |        |                 |                  |                   |            |                          |
| 11504-037          | ADC Therapeutics SA |               | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER | Issued | 07720048.3      | 6/22/2017        | 2032701           | 11/27/2013 | European Patent Office   |
| 11504-038          | ADC Therapeutics SA |               | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER | Issued | 2009-515683     | 6/22/2017        | 5564249           | 6/20/2014  | Japan                    |
| 11504-039          | ADC Therapeutics SA |               | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER | Issued | 12/305,648      | 6/22/2017        | 8216582           | 7/10/2012  | United States of America |
| 11504-126          | ADC Therapeutics SA |               | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER | Issued | 12163634.4      | 6/22/2017        | 2502628           | 12/14/2016 | European Patent Office   |
| 11504-159          | ADC Therapeutics SA |               | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER | Issued | 2014-24778      | 6/22/2017        | 5589149           | 8/1/2014   | Japan                    |
| 11504-240          | ADC Therapeutics    |               | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES                    | Issued | 1620346S.0      | 6/22/2017        | 3231442           | 12/25/2019 | European Patent Office   |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                                         | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|---------------|-------------------------------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
|                    | SA                  |               | INVOLVED IN CANCER                                                            |         |                 |                  |                   |            |                          |
| 11504-247          | ADC Therapeutics SA |               | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER                  | Pending | 17112476.9      | 6/22/2017        |                   |            | Hong Kong                |
| 11504-251          | ADC Therapeutics SA |               | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER                  | Pending | 15/863,594      | 6/22/2017        |                   |            | United States of America |
| 11504-074          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN | Issued  | 2,740,900       | 11/3/2009        | 2740900           | 9/24/2019  | Canada                   |
| 11504-075          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN | Issued  | 13/127,439      | 11/3/2009        | 9855291           | 2/2/2018   | United States of America |
| 11504-077          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN | Issued  | 2011-533500     | 11/3/2009        | 5781932           | 7/24/2015  | Japan                    |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                                         | Status | Application No.   | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|---------------|-------------------------------------------------------------------------------|--------|-------------------|------------------|-------------------|------------|--------------------------|
| 11504-078          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN | Issued | 2009321508        | 11/3/2009        | 2009321508        | 6/25/2015  | Australia                |
| 11504-079          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN | Issued | 200980143778.5    | 11/3/2009        | ZL200980143778.5  | 8/27/2014  | China                    |
| 11504-082          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN | Issued | Mx/a/2011/0046684 | 11/3/2009        | 336869            | 2/4/2016   | Mexico                   |
| 11504-084          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN | Issued | 592432            | 11/3/2009        | 592432            | 4/30/2013  | New Zealand              |
| 11504-090          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN | Issued | 13/187,424        | 11/3/2009        | 8580257           | 11/12/2013 | United States of America |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                                                | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|---------------|--------------------------------------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| 11504-233          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN        | Pending | 16171408.4      | 11/3/2009        |                   |            | European Patent Office   |
| 11504-242          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN        | Pending | 17108005.7      | 11/3/2009        |                   |            | Hong Kong                |
| 11504-248          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN        | Pending | 150833.753      | 11/3/2009        |                   |            | United States of America |
| 11504-260          | ADC Therapeutics SA |               | ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN        | Pending | 3,050,455       | 11/3/2009        |                   |            | Canada                   |
| 11504-144          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 2012234754      | 3/28/2012        | 2012234754        | 1/12/2017  | Australia                |



IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                                                | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction           |
|--------------------|---------------------|---------------|--------------------------------------------------------------------------------------|---------|------------------|------------------|-------------------|------------|------------------------|
| 11504-145          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | BR112013025193-0 | 3/28/2012        |                   |            | Brazil                 |
| 11504-146          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 2,829,105        | 3/28/2012        | 2829105           | 9/24/2019  | Canada                 |
| 11504-147          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 201280015597.6   | 3/28/2012        | ZL20280015597.6   | 6/29/2016  | China                  |
| 11504-148          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 201391423        | 3/28/2012        |                   |            | Eurasian Patent Office |
| 11504-149          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 12765926.6       | 3/28/2012        | 2691421           | 11/9/2016  | European Patent Office |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                                                | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|--------------------|---------------------|---------------|--------------------------------------------------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| 11504-150          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 3184/KOLNP/2013  | 3/28/2012        |                   |            | India        |
| 11504-151          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 228434           | 3/28/2012        | 228434            | 9/1/2018   | Israel       |
| 11504-152          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 2014-501372      | 3/28/2012        | 6294221           | 2/23/2018  | Japan        |
| 11504-153          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | Mx/a/2013/011354 | 3/28/2012        | 352373            | 11/22/2017 | Mexico       |
| 11504-154          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 615694           | 3/28/2012        | 615694            | 5/1/2015   | New Zealand  |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                                                | Status | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|---------------|--------------------------------------------------------------------------------------|--------|-----------------|------------------|-------------------|------------|--------------------------|
| 11504-155          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued | 10-2013-7026861 | 3/28/2012        | 10-1993259        | 6/20/2019  | Republic of Korea        |
| 11504-156          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued | 2013/07027      | 3/28/2012        | 2013/07027        | 8/31/2016  | South Africa             |
| 11504-157          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued | 14/036,204      | 3/28/2012        | 8937163           | 1/20/2015  | United States of America |
| 11504-189          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued | 14107223.8      | 3/28/2012        | 1193835           | 3/2/2018   | Hong Kong                |
| 11504-215          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued | 14/558,186      | 3/28/2012        | 9393302           | 7/19/2016  | United States of America |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                                                | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|---------------|--------------------------------------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| 11504-218          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 2,888,908       | 3/28/2012        |                   |            | Canada                   |
| 11504-224          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 2,893,376       | 3/28/2012        |                   |            | Canada                   |
| 11504-231          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 15/137,368      | 3/28/2012        | 9828426           | 11/28/2017 | United States of America |
| 11504-236          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 201610534416.0  | 3/28/2012        |                   |            | China                    |
| 11504-238          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 16190193.9      | 3/28/2012        | 3173427           | 6/19/2019  | European Patent Office   |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                                                | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|---------------|--------------------------------------------------------------------------------------|---------|------------------|------------------|-------------------|------------|--------------------------|
| 11504-245          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 15/811,545       | 3/28/2012        | 10597450          | 3/24/2020  | United States of America |
| 11504-246          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 17112341.2       | 3/28/2012        | 1238268           | 2/7/2020   | Hong Kong                |
| 11504-249          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | Mx/a/2017/014913 | 3/28/2012        |                   |            | Mexico                   |
| 11504-250          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Issued  | 2017-235147      | 3/28/2012        | 6650432           | 2/19/2020  | Japan                    |
| 11504-256          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 19155812.1       | 3/28/2012        |                   |            | European Patent Office   |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                                                                                | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|---------------|--------------------------------------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| 11504-258          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 266452          | 3/28/2012        |                   |            | Israel                   |
| 11504-259          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Allowed | 10-2019-7017755 | 3/28/2012        |                   |            | Republic of Korea        |
| 11504-265          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 16707,482       | 3/28/2012        |                   |            | United States of America |
| 11504-266          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 20001302.7      | 3/28/2012        |                   |            | Hong Kong                |
| 11504-268          | ADC Therapeutics SA |               | ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF | Pending | 2020-5907       | 3/28/2012        |                   |            | Japan                    |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                             | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction           |
|--------------------|---------------------|---------------|-----------------------------------|---------|------------------|------------------|-------------------|------------|------------------------|
| 11504-163          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 2013209234       | 1/9/2013         | 2013209234        | 1/22/2018  | Australia              |
| 11504-164          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Pending | BR112014016723-0 | 1/9/2013         |                   |            | Brazil                 |
| 11504-165          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Pending | 2,857,400        | 1/9/2013         |                   |            | Canada                 |
| 11504-166          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 201380005017 X   | 1/9/2013         | ZL201380005017 X  | 3/3/2020   | China                  |
| 11504-167          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 201491352        | 1/9/2013         | 034414            | 2/5/2020   | Eurasian Patent Office |
| 11504-168          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 13735811.5       | 1/9/2013         | 2802351           | 3/27/2019  | European Patent Office |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                             | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction      |
|--------------------|---------------------|---------------|-----------------------------------|---------|------------------|------------------|-------------------|------------|-------------------|
| 11504-171          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 2014-551488      | 1/9/2013         | 6282597           | 2/2/2018   | Japan             |
| 11504-172          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | Mx/a/2014/008410 | 1/9/2013         | 366973            | 8/1/2019   | Mexico            |
| 11504-173          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 625758           | 1/9/2013         | 625758            | 8/30/2016  | New Zealand       |
| 11504-174          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 10-2014-7018877  | 1/9/2013         | 10-2102239        | 4/13/2020  | Republic of Korea |
| 11504-175          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Pending | 2014/04798       | 1/9/2013         |                   |            | South Africa      |
| 11504-222          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 15104275.1       | 1/9/2013         | HK1203816         | 12/29/2019 | Hong Kong         |



IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant | Title                             | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------|---------------------|---------------|-----------------------------------|---------|------------------|------------------|-------------------|------------|--------------------------|
| 11504-243          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 254964           | 1/9/2013         |                   |            | Israel                   |
| 11504-244          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Issued  | 2017-213873      | 1/9/2013         | 6392435           | 8/31/2018  | Japan                    |
| 11504-254          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Pending | 16164,656        | 1/9/2013         |                   |            | United States of America |
| 11504-255          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Pending | 19156516.7       | 1/9/2013         |                   |            | European Patent Office   |
| 11504-257          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Pending | 202010098137.0   | 1/9/2013         |                   |            | China                    |
| 11504-261          | ADC Therapeutics SA |               | METHOD FOR TREATING BREAST CANCER | Pending | MX/a/2019/009121 | 1/9/2013         |                   |            | Mexico                   |

IP Pledge Agreement

| Internal Reference | 1st Applicant       | 2nd Applicant     | Title                                               | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction           |
|--------------------|---------------------|-------------------|-----------------------------------------------------|---------|-----------------|------------------|-------------------|------------|------------------------|
| 11504-262          | ADC Therapeutics SA |                   | METHOD FOR TREATING BREAST CANCER                   | Pending | 201992513       | 1/9/2013         |                   |            | Eurasian Patent Office |
| 11504-267          | ADC Therapeutics SA |                   | METHOD FOR TREATING BREAST CANCER                   | Pending | 42020003175.5   | 1/9/2013         |                   |            | Hong Kong              |
| 007345390          | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Pending | 15897835        | 2/15/18          |                   |            | United States          |
| 007346323          | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES           | Pending | 15911592        | 3/5/18           |                   |            | United States          |
| 007330178          | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | Pending | 15884665        | 1/31/18          |                   |            | United States          |
| 007305261          | ADC Therapeutics SA | MedImmune Limited | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES  | Pending | 15566639        | 10/13/17         |                   |            | United States          |

IP Pledge Agreement

| Internal Reference         | 1st Applicant       | 2nd Applicant     | Title                                                 | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction  |
|----------------------------|---------------------|-------------------|-------------------------------------------------------|---------|-----------------|------------------|-------------------|------------|---------------|
| 007112873                  | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES             | Granted | 14434816        | 4/10/15          | 9931414           | 4/3/18     | United States |
| 007112030                  | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES             | Granted | 14434823        | 4/10/15          | 9931415           | 4/3/18     | United States |
| 007112170                  | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES   | Granted | 14434826        | 4/10/15          | 9919056           | 3/20/18    | United States |
| Patent 1 KR (SGNAT-101KR1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | Granted | 10-2015-7012364 | 11/10/2013       | 10-1986404        | 30/05/2019 | South Korea   |
| Patent 4 KR (SGNAT-104KR1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES             | Granted | 10-2015-7012366 | 11/10/2013       | 10-1995619        | 26/06/2019 | South Korea   |
| Patent 9 KR (SGNAT-109KR1) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES   | Granted | 10-2015-7012368 | 11/10/2013       | 10-1995671        | 26/06/2019 | South Korea   |

IP Pledge Agreement

| Internal Reference               | 1st Applicant       | 2nd Applicant     | Title                                  | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|----------------------------------|---------------------|-------------------|----------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| Patent 28 US Cont (SGNAT-128WO1) | ADC Therapeutics SA | Medimmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 16/731528       | 15/04/2015       |                   |            | United States of America |
| Patent 28 EP(SGNAT-128WO1)       | ADC Therapeutics SA | Medimmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 16716583.6      | 15/04/2016       |                   |            | European Patent          |
| Patent 28 AU (SGNAT-128WO1)      | ADC Therapeutics SA | Medimmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 2016249877      | 15/04/2016       |                   |            | Australia                |
| Patent 28 BR (SGNAT-128WO1)      | ADC Therapeutics SA | Medimmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | BR1120170222566 | 15/04/2016       |                   |            | Brazil                   |
| Patent 28 CA (SGNAT-128WO1)      | ADC Therapeutics SA | Medimmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 2981920         | 15/04/2015       |                   |            | Canada                   |
| Patent 28 CN (SGNAT-128WO1)      | ADC Therapeutics SA | Medimmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 201680022066.8  | 15/04/2016       |                   |            | China                    |

IP Pledge Agreement

| Internal Reference          | 1st Applicant       | 2nd Applicant     | Title                                  | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|-----------------------------|---------------------|-------------------|----------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| Patent 28 IN (SGNAT-128WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 201727039662     | 15/04/2016       |                   |            | India        |
| Patent 28 JP (SGNAT-128WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 2017-553879      | 15/04/2016       |                   |            | Japan        |
| Patent 28 MX (SGNAT-128WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | MX/A/2017/013154 | 15/04/2016       |                   |            | Mexico       |
| Patent 28 NZ (SGNAT-128WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 735885           | 15/04/2016       |                   |            | New Zealand  |
| Patent 28 ZA (SGNAT-128WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 2017/06704       | 15/04/2016       |                   |            | South Africa |
| Patent 28 KR (SGNAT-128WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 10-2017-7030351  | 15/04/2016       |                   |            | South Korea  |

IP Pledge Agreement

| Internal Reference               | 1st Applicant       | 2nd Applicant     | Title                                  | Status  | Application No. | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|----------------------------------|---------------------|-------------------|----------------------------------------|---------|-----------------|------------------|-------------------|------------|--------------------------|
| Patent 31 US Cont (SGNAT-131WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 16/684222       | 15/04/2015       |                   |            | United States of America |
| Patent 31 WO (SGNAT-131WO1)      | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 16716589.3      | 15/04/2016       |                   |            | European Patent          |
| Patent 31 AU (SGNAT-131WO1)      | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 2016247584      | 15/04/2016       |                   |            | Australia                |
| Patent 31 BR (SGNAT-131WO1)      | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | BR1120170222582 | 15/04/2016       |                   |            | Brazil                   |
| Patent 31 CA (SGNAT-131WO1)      | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 2982522         | 15/04/2015       |                   |            | Canada                   |
| Patent 31 CN (SGNAT-131WO1)      | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 201680022088.4  | 15/04/2016       |                   |            | China                    |

IP Pledge Agreement

| Internal Reference          | 1st Applicant       | 2nd Applicant     | Title                                  | Status  | Application No.  | Application Date | Granted Right No. | Grant Date | Jurisdiction |
|-----------------------------|---------------------|-------------------|----------------------------------------|---------|------------------|------------------|-------------------|------------|--------------|
| Patent 31 IN (SGNAT-131WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 201727040436     | 15/04/2016       |                   |            | India        |
| Patent 31 JP (SGNAT-131WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 2017-554082      | 15/04/2016       |                   |            | Japan        |
| Patent 31 MX (SGNAT-131WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | MX/A/2017/013167 | 15/04/2016       |                   |            | Mexico       |
| Patent 31 NZ (SGNAT-131WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 736010           | 15/04/2016       |                   |            | New Zealand  |
| Patent 31 ZA (SGNAT-131WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 2017/06745       | 15/04/2016       |                   |            | South Africa |
| Patent 31 KR (SGNAT-131WO1) | ADC Therapeutics SA | MedImmune Limited | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Pending | 10-2017-7030358  | 15/04/2016       |                   |            | South Korea  |

IP Pledge Agreement

| Internal Reference             | 1st Applicant       | 2nd Applicant     | Title                                     | Status  | Application No.   | Application Date | Granted Right No. | Grant Date | Jurisdiction             |
|--------------------------------|---------------------|-------------------|-------------------------------------------|---------|-------------------|------------------|-------------------|------------|--------------------------|
| Patent 55 US (SGAT-155US-1)    | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 16/484328         | 08/02/2018       |                   |            | United States of America |
| Patent 55 KRdiv (SGAT-155KR-2) | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | Pending | 10-2020-7007470   | 08/02/2018       |                   |            | South Korea              |
| Patent 101 WO                  | ADC Therapeutics SA | MedImmune Limited | TREATMENT OF CAR T-CELL TOXICITY          | Pending | PCT/EP2019/053165 | 08/02/2019       |                   |            | International            |
| Patent 106 WO                  | ADC Therapeutics SA | MedImmune Limited | PYRROLOBENZODIAZEPINE RESISTANCE          | Pending | PCT/EP2019/086079 | 18/12/2019       |                   |            | International            |
| Patent 109 & 112 WO            | ADC Therapeutics SA | MedImmune Limited | MOLECULAR ADJUVANT                        | Pending | PCT/EP2019/063262 | 22/05/2019       |                   |            | International            |
| Patent 114 WO                  | ADC Therapeutics SA | MedImmune Limited | COMBINATION THERAPY                       | Pending | PCT/EP2019/068287 | 08/07/2019       |                   |            | International            |



IP Pledge Agreement

| Internal Reference    | 1st Applicant             | 2nd Applicant        | Title               | Status  | Application No.   | Application Date | Granted Right No. | Grant Date | Jurisdiction                |
|-----------------------|---------------------------|----------------------|---------------------|---------|-------------------|------------------|-------------------|------------|-----------------------------|
| Patent 116<br>WO      | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | COMBINATION THERAPY | Pending | PCT/EP2019/073212 | 30/08/2019       |                   |            | International               |
| Patent 118b<br>USprov | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | DOSAGE REGIME       | Pending | 62/883867         | 07/08/2019       |                   |            | United States of<br>America |
| Patent 118<br>WO      | ADC<br>Therapeutics<br>SA | MedImmune<br>Limited | DOSAGE REGIME       | Pending | PCT/EP2019/082464 | 25/11/2019       |                   |            | International               |

## C. Trademarks

| Trademark                       | Appl. Date        | Reg. Date         | Appl. No.  | Reg. No.  | Jurisdiction                 |
|---------------------------------|-------------------|-------------------|------------|-----------|------------------------------|
| ADC THERAPEUTICS<br>(WORD MARK) | March 22, 2012    | December 3, 2013  | 85577148   | 4445250   | United States                |
| ADC THERAPEUTICS<br>(WORD MARK) | January 11, 2016  | July 17, 2018     | 86983736   | 5516438   | United States                |
| ADC THERAPEUTICS<br>(WORD MARK) | February 12, 2016 | October 23, 2017  | 015101471  | 015101471 | The European Union Trademark |
| ADC THERAPEUTICS<br>(WORD MARK) | May 8, 2018       |                   | 72974-2018 |           | Switzerland                  |
| ADC THERAPEUTICS<br>(WORD MARK) | May 8, 2018       | December 10, 2018 | 201805966  | 301522    | Norway                       |
| ADC THERAPEUTICS<br>(WORD MARK) | May 8, 2018       | August 2, 2019    | 2018059483 | 6168443   | Japan                        |
| ADC THERAPEUTICS<br>(WORD MARK) | May 9, 2018       |                   | 1898283    |           | Canada                       |

| Trademark                       | Appl. Date        | Reg. Date         | Appl. No.   | Reg. No.  | Jurisdiction                 |
|---------------------------------|-------------------|-------------------|-------------|-----------|------------------------------|
| ADC THERAPEUTICS<br>(WORD MARK) | May 8, 2018       |                   | 2082057     |           | Australia                    |
| ADC THERAPEUTICS<br>LOGO        | January 11, 2016  | July 17, 2018     | 86983735    | 5516437   | United States                |
| ADC THERAPEUTICS<br>LOGO        | February 12, 2016 | October 18, 2017  | 015103583   | 015103583 | The European Union Trademark |
| ADC THERAPEUTICS<br>LOGO        | May 8, 2018       |                   | 72975-2018  |           | Switzerland                  |
| ADC THERAPEUTICS<br>LOGO        | May 8, 2018       | December 10, 2018 | 201805965   | 301521    | Norway                       |
| ADC THERAPEUTICS<br>LOGO        | May 8, 2018       | November 9, 2018  | 1092480     | 1092480   | New Zealand                  |
| ADC THERAPEUTICS<br>LOGO        | May 8, 2018       | August 2, 2019    | 2018-059484 | 6168444   | Japan                        |
| ADC THERAPEUTICS<br>LOGO        | May 9, 2018       |                   | 1898284     |           | Canada                       |
| ADC THERAPEUTICS                | May 8, 2018       |                   | 2082053     |           | Australia                    |

| Trademark | Appl. Date      | Reg. Date | Appl. No. | Reg. No. | Jurisdiction                 |
|-----------|-----------------|-----------|-----------|----------|------------------------------|
| LOGO      |                 |           |           |          |                              |
| ADCROZ    | July 9, 2019    |           | 88506312  |          | United States                |
| ADCROZ    | March 26, 2020  |           | 1512089   |          | Ukraine                      |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | Turkey                       |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | The European Union Trademark |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | Switzerland                  |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | Singapore                    |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | Russian Federation           |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | Republic of Korea            |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | Norway                       |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | New Zealand                  |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | Mexico                       |
| ADCROZ    | January 7, 2020 |           | 1512089   |          | Japan                        |

IP Pledge Agreement

| Trademark        | Appl. Date        | Reg. Date       | Appl. No. | Reg. No.  | Jurisdiction                 |
|------------------|-------------------|-----------------|-----------|-----------|------------------------------|
| ADCROZ           | January 7, 2020   |                 | 1512089   |           | Israel                       |
| ADCROZ           | January 7, 2020   | January 7, 2020 | A0093087  | 1512089   | International                |
| ADCROZ           | January 7, 2020   |                 | 1512089   |           | India                        |
| ADCROZ           | January 7, 2020   |                 | 1512089   |           | Iceland                      |
| ADCROZ           | January 7, 2020   |                 | 1512089   |           | China P.R.                   |
| ADCROZ           | January 7, 2020   |                 | 1512089   |           | Canada                       |
| ADCROZ           | January 7, 2020   |                 | 1512089   |           | Brazil                       |
| ADCROZ           | January 7, 2020   |                 | 1512089   |           | Australia                    |
| ADCROZ           | January 6, 2020   |                 | 109000680 |           | Taiwan                       |
| ADCROZ           | January 6, 2020   |                 | 305161923 |           | Hong Kong                    |
| ADCT (WORD MARK) | January 11, 2016  |                 | 86871990  |           | United States                |
| ADCT (WORD MARK) | February 12, 2016 | June 10, 2016   | 015101553 | 015101553 | The European Union Trademark |
| ADCT LOGO        | February 13, 2018 |                 | 87796629  |           | United States                |

| Trademark       | Appl. Date       | Reg. Date | Appl. No. | Reg. No. | Jurisdiction                 |
|-----------------|------------------|-----------|-----------|----------|------------------------------|
| CATCHLIGHT      | October 21, 2019 |           | 88662016  |          | United States                |
| CATCHLIGHT LOGO | October 21, 2019 |           | 88662133  |          | United States                |
| ZYNLONTA        | July 9, 2019     |           | 88506358  |          | United States                |
| ZYNLONTA        | March 26, 2020   |           | 1512100   |          | Ukraine                      |
| ZYNLONTA        | January 7, 2020  |           | 1512100   |          | Turkey                       |
| ZYNLONTA        | January 7, 2020  |           | 1512100   |          | The European Union Trademark |
| ZYNLONTA        | January 6, 2020  |           | 109000679 |          | Taiwan                       |
| ZYNLONTA        | January 7, 2020  |           | 1512100   |          | Switzerland                  |
| ZYNLONTA        | January 7, 2020  |           | 1512100   |          | Singapore                    |
| ZYNLONTA        | January 7, 2020  |           | 1512100   |          | Russian Federation           |
| ZYNLONTA        | January 7, 2020  |           | 1512100   |          | Republic of Korea            |
| ZYNLONTA        | January 7, 2020  |           | 1512100   |          | Norway                       |
| ZYNLONTA        | January 7, 2020  |           | 1512100   |          | New Zealand                  |

| Trademark                       | Appl. Date      | Reg. Date       | Appl. No. | Reg. No. | Jurisdiction  |
|---------------------------------|-----------------|-----------------|-----------|----------|---------------|
| ZYNLONTA                        | January 7, 2020 |                 | 1512100   |          | Mexico        |
| ZYNLONTA                        | January 7, 2020 |                 | 1512100   |          | Japan         |
| ZYNLONTA                        | January 7, 2020 |                 | 1512100   |          | Israel        |
| ZYNLONTA                        | January 7, 2020 | January 7, 2020 | A6093089  | 1512100  | International |
| ZYNLONTA                        | January 7, 2020 |                 | 1512100   |          | India         |
| ZYNLONTA                        | January 7, 2020 |                 | 1512100   |          | Iceland       |
| ZYNLONTA                        | January 7, 2020 |                 | 1512100   |          | China P.R.    |
| ZYNLONTA                        | January 7, 2020 |                 | 1512100   |          | Canada        |
| ZYNLONTA                        | January 7, 2020 |                 | 1512100   |          | Brazil        |
| ZYNLONTA                        | January 7, 2020 |                 | 1512100   |          | Australia     |
| ZYNLONTA                        | January 6, 2020 |                 | 305161996 |          | Hong Kong     |
| ADC THERAPEUTICS<br>(WORD MARK) | April 28, 2020  |                 | 327223    |          | Israel        |

| Trademark                       | Appl. Date     | Reg. Date | Appl. No.  | Reg. No. | Jurisdiction |
|---------------------------------|----------------|-----------|------------|----------|--------------|
| ADC THERAPEUTICS<br>(WORD MARK) | April 28, 2020 |           | m202008007 |          | Ukraine      |
| ADC THERAPEUTICS<br>LOGO        | April 28, 2020 |           | 327225     |          | Israel       |
| ADC THERAPEUTICS<br>LOGO        | April 28, 2020 |           | m202008009 |          | Ukraine      |
| ADCROZ                          | April 24, 2020 |           | 3889094    |          | Argentina    |
| ZYNLONTA                        | April 24, 2020 |           | 3889095    |          | Argentina    |



---

**D. Domain Names**

---

adc-axl.com  
adc-cd19.com  
adc-cd22.com  
adc-cd25.com  
adc-her2.com  
adc-muc1.com  
adc-psma.com  
adc-tx.com  
adcenko.com  
adcroz.com  
adct-301.com  
adct-401.com  
adct-402.com  
adct-501.com  
adct-502.com  
adct-601.com  
adct-602.com  
adct-701.com  
adct-801.com  
adct-901.com  
adct-rd.com  
adct301.com  
adct401.com  
adct402.com  
adct501.com  
adct502.com  
adct601.com  
adct602.com  
adct701.com  
adct801.com  
adct901.com  
adctbio.com  
adctdev.com  
ADCTTHERAPEUTICS.COM  
adcthr.com  
adctrd.com

adctrx.com  
adctsa.com  
adloncare.com  
adloncta.com  
adlymca.com  
aremyzta.com  
cami-t.ch  
cami-t.co.uk  
cami-t.com  
camidanlumab-tesirine.ch  
camidanlumab-tesirine.co.uk  
camidanlumab-tesirine.com  
camidanlumab.ch  
camidanlumab.co.uk  
camidanlumab.com  
camidanlumabtesirine.ch  
camidanlumabtesirine.co.uk  
camidanlumabtesirine.com  
limfyxta.com  
lonadca.com  
lonca-b.ch  
lonca-b.co.uk  
lonca-b.com  
lonca-t.ch  
lonca-t.co.uk  
lonca-t.com  
lonca.ch  
lonca.co.uk  
loncab.ch  
loncab.co.uk  
loncadcaide.com  
loncadceutix.com  
loncafyte.com  
loncastuximab-tesirine.ch  
loncastuximab-tesirine.co.uk  
loncastuximab-tesirine.com  
loncastuximab.ch  
loncastuximab.co.uk  
loncastuximab.com  
loncastuximabtesirine.ch  
loncastuximabtesirine.co.uk

loncastuximabtesirine.com  
loncat.ch  
loncat.co.uk  
loncattend.com  
lontadca.com  
synadca.com  
THEADCCOMPANY.CO.UK  
THEADCCOMPANY.COM  
thxlp.com  
viqtior.com  
xixadca.com  
xixvias.com  
zoloncos.com  
zynlonta.com

---

**E. Others**

N/A

---

**Schedule 2a: Form of Notification Letter to the World Institute of Intellectual Property Organisation**

**Registered Mail**

World Intellectual Property Organization  
 34, chemin des Colombettes  
 P.O. Box 18  
 1211 Geneva 20  
 Switzerland

[Place, date]

**Pledge of Trademarks**

Dear Sirs

We hereby inform you that we entered into a pledge agreement dated [...] (the **Agreement**, enclosed herewith) based on which we have pledged to [*Name and Address of the Security Agent*] (the **Security Agent**) the following trademarks, i.e.:

[...]

The Security Agent is represented in Switzerland by Walder Wyss Ltd., Seefeldstrasse 123, 8008 Zurich (Attn [*Partner*]).

We herewith kindly ask you to register this pledge in the international trademark register. For this purpose, we hereto enclose the duly filled out form[s] [MM 19] and would be pleased if you could send a confirmation of the registration of the pledge in the international trademark register to us and also to the aforementioned representative of the Security Agent.

Yours faithfully

[the Pledgor]

\_\_\_\_\_  
 Name:

Title:

\_\_\_\_\_  
 Name:

Title:

Annexes: the Agreement and Forms MM19 WIPO

---

**Schedule 2b: Form of Notification Letter to Swiss Federal Institute of Intellectual Property (trademarks)**

**Einschreiben**

Institut für Geistiges Eigentum  
Stauffacherstrasse 65/59g  
3003 Bern

**Verpfändung von Marken**

Sehr geehrte Damen und Herren

Wir zeigen Ihnen hiermit an, dass wir unsere Marken

*[Nos. of Swiss Trademarks]*

an

*[Name and address of Security Agent]*, und die von ihr vertretenen Gläubiger,

in der Schweiz vertreten durch:

Walder Wyss AG, *[Partner]*, Seefeldstrasse 123, 8008 Zürich, als hiesiger Vertreter der Pfandgläubiger,

verpfändet haben.

Wir ersuchen Sie um Eintragung des Pfandrechts über die genannten Marken im Schweizerischen Markenregister und die Zustellung einer Eintragungsbestätigung an die hiesigen Vertreter der Pfandgläubigerin.

Mit freundlichen Grüssen

*[Name des Pledgors]*

---

Name:

Titel:

---

Name:

Titel:

---

**Schedule 2c: Form of Notification Letter to Swiss Federal Institute of Intellectual Property (patents)**

**Einschreiben**

Institut für Geistiges Eigentum  
Stauffacherstrasse 65/59g  
3003 Bern

**Verpfändung von Patenten**

Sehr geehrte Damen und Herren

Wir zeigen Ihnen hiermit an, dass wir unsere Anteile am schweizerischen und liechtensteinischen Teil der europäischen Patente

*[No. of European Patent effective in Switzerland]*

an

*[Name and address of Pledgee],*

in der Schweiz und Liechtenstein vertreten durch:

Walder Wyss AG, *[Partner]*, Seefeldstrasse 123, 8008 Zürich, als hiesiger Vertreter der Pfandgläubiger,

verpfändet haben.

Wir ersuchen Sie um Eintragung des Pfandrechts über die genannten Anteile im schweizerischen Register für europäische Patente und die Zustellung einer Eintragungsbestätigung an die hiesigen Vertreter der Pfandgläubigerin.

Mit freundlichen Grüssen

*[Name des Pledgors]*

---

Name:

Titel:

---

Name:

Titel: